-DOCSTART- -X- O O
This	O
study	O
provides	O
initial	O
,	O
correlational	O
evidence	O
for	O
mental	B-HEALTH CONDITION
health	I-HEALTH CONDITION
and	O
personality	B-OUTCOME
benefits	I-OUTCOME
associated	O
with	O
microdosing	B-DRUG
psychedelics	I-DRUG
.	O
While	O
anecdotal	O
reports	O
of	O
microdosing	B-DRUG
benefits	O
have	O
existed	O
for	O
some	O
time	O
(	O
Fadiman	O
,	O
2011	O
)	O
,	O
this	O
study	O
marks	O
the	O
first	O
formal	O
study	O
of	O
the	O
topic	O
.	O
Additionally	O
,	O
the	O
use	O
of	O
a	O
pre	O
-	O
registered	O
study	O
design	O
sets	O
a	O
precedent	O
for	O
responsible	O
and	O
replicable	O
psychedelic	B-DRUG
microdosing	I-DRUG
research	O
.	O
To	O
add	O
depth	O
to	O
the	O
current	O
discussion	O
,	O
a	O
full	O
epidemiological	O
report	O
(	O
Rosenbaum	O
et	O
al	O
.	O
,	O
2018	O
)	O
and	O
a	O
Grounded	O
Theory	O
analysis	O
of	O
qualitative	O
outcomes	O
(	O
Anderson	O
et	O
al	O
.	O
,	O
2018	O
)	O
are	O
forthcoming	O
.	O
The	O
results	O
of	O
the	O
present	O
study	O
suggest	O
that	O
there	O
is	O
a	O
significant	O
relationship	O
between	O
microdosing	B-DRUG
experience	O
and	O
measures	O
of	O
mental	B-HEALTH CONDITION
health	I-HEALTH CONDITION
and	O
flourishing	O
including	O
lower	B-OUTCOME
dysfunctional	I-OUTCOME
attitudes	I-OUTCOME
and	O
negative	B-OUTCOME
emotionality	I-OUTCOME
,	O
higher	B-OUTCOME
wisdom	I-OUTCOME
and	O
open	B-OUTCOME
-	I-OUTCOME
mindedness	I-OUTCOME
,	O
and	O
higher	B-OUTCOME
creativity	I-OUTCOME
and	O
affect	B-OUTCOME
-	I-OUTCOME
valence	I-OUTCOME
.	O
These	O
findings	O
are	O
the	O
initial	O
evidence	O
that	O
warrants	O
RCTs	O
to	O
directly	O
test	O
safety	O
and	O
therapeutic	B-OUTCOME
efficacy	I-OUTCOME
.	O
With	O
approximately	O
30,000	O
users	O
subscribing	O
to	O
the	O
/r	O
/	O
microdosing	B-DRUG
subreddit	O
and	O
thousands	O
more	O
reading	O
media	O
reports	O
on	O
microdosing	B-DRUG
this	O
growing	O
community	O
continues	O
to	O
explore	O
microdosing	B-DRUG
and	O
this	O
growing	O
community	O
effects	O
.	O
It	O
is	O
our	O
hope	O
that	O
scientific	O
reporting	O
can	O
help	O
to	O
clarify	O
and	O
inform	O
the	O
public	O
about	O
the	O
nature	O
of	O
microdosing	B-DRUG
’s	O
putative	B-OUTCOME
effects	I-OUTCOME
and	O
that	O
this	O
new	O
paradigm	O
helps	O
shape	O
future	O
psychedelic	O
research	O
.	O
our	O
hope	O
that	O
researchers	O
will	O
draw	O
on	O
our	O
shared	O
resources	O
(	O
https://osf.io/g5cwy/	O
)	O
and	O
pre	O
-	O
register	O
studies	O
of	O
researchers	O
own	O
so	O
that	O
psychedelic	O
science	O
will	O
be	O
built	O
upon	O
strong	O
research	O
practices	O
.	O
Insights	O
from	O
these	O
and	O
other	O
studies	O
will	O
form	O
the	O
backbone	O
of	O
future	O
research	O
into	O
microdosing	B-DRUG
psychedelics	I-DRUG
.	O
-DOCSTART- -X- O O
In	O
summary	O
,	O
four	O
years	O
on	O
from	O
the	O
publication	O
of	O
the	O
original	O
entropic	O
brain	B-NEURAL MECHANISM/CORRELATE
hypothesis	O
,	O
the	O
present	O
paper	O
has	O
sought	O
to	O
reflect	O
on	O
the	O
present	O
paper	O
influence	O
,	O
reliability	O
and	O
future	O
scientific	O
and	O
clinical	O
value	O
.	O
The	O
position	O
is	O
maintained	O
that	O
entropy	B-OUTCOME
represents	O
a	O
uniquely	O
powerful	O
bridging	O
tool	O
for	O
human	O
neuroscience	O
that	O
will	O
enable	O
a	O
better	O
understanding	B-OUTCOME
of	I-OUTCOME
the	I-OUTCOME
mind	I-OUTCOME
-	I-OUTCOME
brain	I-OUTCOME
relationship	I-OUTCOME
and	O
mechanics	O
of	O
consciousness	B-SUBJECTIVE EXPERIENCE
,	O
including	O
how	O
we	O
may	O
treat	O
The	O
position	O
abnormalities	O
.	O
-DOCSTART- -X- O O
In	O
patients	O
with	O
treatment	B-HEALTH CONDITION
-	I-HEALTH CONDITION
resistant	I-HEALTH CONDITION
depression	I-HEALTH CONDITION
treated	O
with	O
psilocybin	B-DRUG
,	O
music	O
was	O
described	O
as	O
having	O
a	O
substantial	O
influence	O
on	O
music	B-OUTCOME
therapeutic	I-OUTCOME
experience	I-OUTCOME
,	O
and	O
selective	O
correlations	O
between	O
the	O
musicexperience	O
and	O
the	O
occurrence	O
of	O
mystical	B-SUBJECTIVE EXPERIENCE
experiences	I-SUBJECTIVE EXPERIENCE
and	O
insightfulness	B-SUBJECTIVE EXPERIENCE
during	O
sessions	O
support	O
this	O
.	O
Patients	O
’	O
experience	B-OUTCOME
of	I-OUTCOME
the	I-OUTCOME
music	I-OUTCOME
,	O
but	O
not	O
drug	B-DRUG
intensity	O
,	O
was	O
predictive	O
of	O
reductions	B-OUTCOME
in	I-OUTCOME
depression	I-OUTCOME
1	O
week	O
later	O
,	O
suggesting	O
that	O
music	O
plays	O
a	O
central	O
mediating	O
role	O
in	O
psychedelic	O
therapy	O
.	O
These	O
findings	O
motivate	O
greater	O
appreciation	O
of	O
music	O
as	O
a	O
key	O
variable	O
in	O
psychedelic	O
therapy	O
and	O
highlight	O
the	O
need	O
for	O
further	O
research	O
to	O
better	O
understand	O
how	O
music	O
interacts	O
with	O
certain	O
personality	O
traits	O
and	O
psychological	B-SUBJECTIVE EXPERIENCE
states	I-SUBJECTIVE EXPERIENCE
to	O
influence	O
the	O
acute	O
experience	O
and	O
longer	B-OUTCOME
-	I-OUTCOME
term	I-OUTCOME
outcomes	I-OUTCOME
of	O
psychedelic	O
therapy	O
-DOCSTART- -X- O O
In	O
conclusion	O
,	O
the	O
present	O
study	O
sought	O
to	O
investigate	O
the	O
effect	O
of	O
LSD	B-DRUG
on	O
mental	B-SUBJECTIVE EXPERIENCE
time	I-SUBJECTIVE EXPERIENCE
travel	I-SUBJECTIVE EXPERIENCE
to	O
the	O
past	O
,	O
present	O
and	O
future	O
.	O
Results	O
revealed	O
a	O
selective	B-OUTCOME
effect	I-OUTCOME
of	O
LSD	B-DRUG
on	O
mental	O
spaces	O
linked	O
to	O
the	O
past	O
,	O
i.e.	O
there	O
were	O
significantly	O
fewer	O
cases	O
of	O
mental	B-SUBJECTIVE EXPERIENCE
time	I-SUBJECTIVE EXPERIENCE
travel	I-SUBJECTIVE EXPERIENCE
to	O
the	O
past	O
under	O
LSD	B-DRUG
than	O
placebo	O
,	O
and	O
this	O
effect	O
correlated	O
with	O
the	O
general	O
intensity	O
of	O
LSD	B-DRUG
’s	O
subjective	B-OUTCOME
effects	I-OUTCOME
.	O
These	O
outcomes	O
shed	O
light	O
on	O
the	O
phenomenon	O
of	O
ego	B-SUBJECTIVE EXPERIENCE
-	I-SUBJECTIVE EXPERIENCE
dissolution	I-SUBJECTIVE EXPERIENCE
and	O
specifically	O
a	O
decomposition	O
of	O
the	O
‘	O
narrative	B-SUBJECTIVE EXPERIENCE
-	I-SUBJECTIVE EXPERIENCE
self	I-SUBJECTIVE EXPERIENCE
’	O
or	O
‘	O
narrative	B-SUBJECTIVE EXPERIENCE
identity	I-SUBJECTIVE EXPERIENCE
’	O
,	O
which	O
is	O
strongly	O
associated	O
with	O
autobiographical	B-SUBJECTIVE EXPERIENCE
thought	I-SUBJECTIVE EXPERIENCE
(	O
Pasupathi	O
and	O
Hoyt	O
,	O
2009	O
)	O
.	O
A	O
specific	O
hypothesis	O
was	O
tested	O
that	O
this	O
phenomenon	O
relates	O
to	O
decreased	B-OUTCOME
DMN	I-OUTCOME
integrity	I-OUTCOME
,	O
and	O
this	O
was	O
supported	O
by	O
the	O
data	O
.	O
The	O
findings	O
were	O
discussed	O
in	O
relation	O
to	O
potential	O
therapeutic	B-OUTCOME
applications	I-OUTCOME
of	O
psychedelic	B-DRUG
drugs	I-DRUG
,	O
with	O
a	O
particular	O
focus	O
on	O
depression	B-HEALTH CONDITION
.	O
Further	O
research	O
is	O
required	O
to	O
investigate	O
the	O
robustness	O
,	O
reliability	O
and	O
specificity	O
of	O
the	O
reported	O
findings	O
.	O
-DOCSTART- -X- O O
The	O
findings	O
from	O
the	O
present	O
study	O
highlight	O
the	O
role	O
of	O
psychological	B-OUTCOME
flexibility	I-OUTCOME
as	O
a	O
mediator	O
of	O
acute	O
psychedelic	B-OUTCOME
effects	I-OUTCOME
and	O
depression	B-HEALTH CONDITION
/	O
anxiety	B-HEALTH CONDITION
outcomes	O
.	O
Future	O
studies	O
should	O
examine	O
the	O
effect	O
of	O
psychedelic	B-DRUG
drug	I-DRUG
administration	O
on	O
psychological	B-OUTCOME
flexibility	I-OUTCOME
in	O
a	O
laboratory	O
setting	O
using	O
a	O
controlled	O
trial	O
design	O
in	O
order	O
to	O
ascertain	O
the	O
causal	O
influences	O
of	O
psychological	O
processes	O
that	O
predict	O
therapeutic	B-OUTCOME
effects	I-OUTCOME
of	O
hallucinogens	B-DRUG
.	O
Such	O
work	O
should	O
include	O
measurement	O
of	O
the	O
core	O
processes	O
of	O
ACT	O
(	O
e.g.	O
,	O
defusion	O
,	O
values	O
,	O
self	O
as	O
context	O
,	O
etc	O
.	O
)	O
in	O
order	O
to	O
examine	O
whether	O
changes	O
in	O
these	O
core	O
processes	O
occur	O
and	O
predict	O
enduring	B-OUTCOME
effects	I-OUTCOME
of	O
psychedelic	B-DRUG
substances	I-DRUG
on	O
therapeutic	B-OUTCOME
outcomes	I-OUTCOME
.	O
If	O
psychological	B-OUTCOME
flexibility	I-OUTCOME
continues	O
to	O
be	O
shown	O
to	O
mediate	O
positive	B-OUTCOME
therapeutic	I-OUTCOME
outcomes	I-OUTCOME
,	O
future	O
research	O
should	O
explore	O
whether	O
such	O
therapeutic	B-OUTCOME
effects	I-OUTCOME
can	O
be	O
further	O
enhanced	O
by	O
using	O
a	O
psychotherapeutic	O
approach	O
to	O
psychedelic	O
-	O
assisted	O
therapy	O
that	O
specifically	O
targets	O
processes	O
of	O
change	O
within	O
a	O
transdiagnostic	O
psychological	B-OUTCOME
flexibility	I-OUTCOME
model	O
.	O
-DOCSTART- -X- O O
In	O
addition	O
to	O
neurobiologial	B-OUTCOME
effects	I-OUTCOME
,	O
psychedelic	B-DRUG
microdosing	I-DRUG
might	O
also	O
impact	O
metabolism	B-OUTCOME
.	O
After	O
correcting	O
for	O
multiple	O
hypothesis	O
testing	O
,	O
male	O
rats	O
administered	O
chronic	O
,	O
intermittent	O
low	O
doses	O
of	O
DMT	B-DRUG
exhibited	O
a	O
trend	O
toward	O
eating	B-OUTCOME
less	I-OUTCOME
food	I-OUTCOME
(	O
p	O
=	O
0.13	O
,	O
Figure	O
S3c	O
)	O
.	O
Similar	O
effects	O
have	O
been	O
observed	O
following	O
administration	O
of	O
ayahuasca	B-DRUG
(	O
60	O
)	O
and	O
various	O
serotonergic	B-DRUG
agonists	I-DRUG
.	O
(	O
61	O
)	O
Surprisingly	O
,	O
despite	O
eating	B-OUTCOME
less	I-OUTCOME
food	I-OUTCOME
than	O
vehicle	O
-	O
treated	O
controls	O
,	O
the	O
DMT	B-DRUG
-	O
treated	O
animals	O
gained	B-OUTCOME
significantly	I-OUTCOME
more	I-OUTCOME
weight	I-OUTCOME
(	O
Figure	O
S3b	O
)	O
.	O
This	O
contrasted	O
with	O
a	O
previous	O
report	O
of	O
chronic	O
ayahuasca	B-DRUG
administration	O
in	O
rats	O
,	O
(	O
60	O
)	O
and	O
the	O
reason	O
for	O
the	O
discrepancy	O
is	O
not	O
immediately	O
obvious	O
.	O
Metabolomics	O
experiments	O
revealed	O
that	O
serum	O
levels	O
of	O
most	O
steroids	O
remained	O
unchanged	O
following	O
psychedelic	B-DRUG
microdosing	I-DRUG
.	O
However	O
,	O
male	O
rats	O
treated	O
with	O
DMT	B-DRUG
did	O
experience	O
a	O
nearly	O
50	B-OUTCOME
%	I-OUTCOME
reduction	I-OUTCOME
in	I-OUTCOME
estradiol	I-OUTCOME
levels	I-OUTCOME
,	O
though	O
the	O
effect	O
was	O
not	O
significant	O
after	O
correcting	O
for	O
multiple	O
hypothesis	O
testing	O
In	O
general	O
,	O
more	O
work	O
needs	O
to	O
be	O
done	O
to	O
identify	O
potential	B-OUTCOME
risks	I-OUTCOME
associated	O
with	O
the	O
increasingly	O
popular	O
practice	O
of	O
psychedelic	B-DRUG
microdosing	I-DRUG
.	O
While	O
psychedelic	B-DRUG
-	O
induced	O
activation	B-OUTCOME
of	I-OUTCOME
mTOR	I-OUTCOME
in	O
young	O
adults	O
might	O
lead	O
to	O
changes	B-OUTCOME
in	I-OUTCOME
neural	I-OUTCOME
plasticity	I-OUTCOME
having	O
beneficial	O
effects	B-OUTCOME
on	I-OUTCOME
mood	I-OUTCOME
and	O
anxiety	B-HEALTH CONDITION
,	O
in	O
some	O
individuals	O
,	O
psychedelic	B-DRUG
microdosing	I-DRUG
could	O
cause	O
overstimulation	B-OUTCOME
of	I-OUTCOME
cortical	I-OUTCOME
neurons	I-OUTCOME
and	O
actually	O
exacerbate	O
symptoms	O
of	O
neuropsychiatric	B-HEALTH CONDITION
disorders	I-HEALTH CONDITION
.	O
Moreover	O
,	O
nothing	O
is	O
known	O
about	O
the	O
effects	O
of	O
psychedelic	B-DRUG
microdosing	I-DRUG
on	O
neurodevelopment	B-NEURAL MECHANISM/CORRELATE
or	O
the	O
aging	O
brain	B-NEURAL MECHANISM/CORRELATE
.	O
As	O
overactivation	B-OUTCOME
of	I-OUTCOME
mTOR	I-OUTCOME
has	O
been	O
proposed	O
to	O
contribute	O
to	O
the	O
development	O
of	O
autism	B-HEALTH CONDITION
spectrum	I-HEALTH CONDITION
disorder	I-HEALTH CONDITION
(	O
ASD	O
)	O
(	O
62	O
)	O
and	O
Alzheimer	B-HEALTH CONDITION
’s	I-HEALTH CONDITION
disease	I-HEALTH CONDITION
(	O
AD	O
)	O
,	O
(	O
63	O
)	O
more	O
research	O
is	O
warranted	O
to	O
fully	O
understand	O
the	O
risks	O
associated	O
with	O
the	O
chronic	O
,	O
intermittent	O
use	O
of	O
psychedelics	B-DRUG
and	O
related	O
psychoplastogens	B-DRUG
While	O
our	O
study	O
only	O
assessed	O
the	O
impact	O
of	O
a	O
single	O
low	O
dose	O
of	O
DMT	B-DRUG
administered	O
on	O
a	O
chronic	O
,	O
intermittent	O
schedule	O
,	O
it	O
is	O
important	O
because	O
it	O
provides	O
critical	O
information	O
about	O
which	O
behaviors	O
are	O
sensitive	O
to	O
psychedelic	B-DRUG
microdosing	I-DRUG
,	O
and	O
which	O
are	O
not	O
,	O
for	O
both	O
males	O
and	O
females	O
.	O
Moreover	O
,	O
it	O
accomplished	O
this	O
using	O
the	O
minimal	O
number	O
of	O
animals	O
possible	O
—	O
an	O
important	O
ethical	O
consideration	O
.	O
Follow	O
-	O
up	O
studies	O
can	O
now	O
hone	O
in	O
on	O
particular	O
behaviors	O
of	O
interest	O
(	O
e.g.	O
,	O
FST	O
or	O
fear	B-OUTCOME
extinction	I-OUTCOME
)	O
and	O
perform	O
dose	O
–	O
response	O
or	O
time	O
–	O
response	O
studies	O
.	O
We	O
still	O
do	O
not	O
know	O
if	O
(	O
1	O
)	O
lower	O
doses	O
would	O
maintain	O
therapeutic	B-OUTCOME
efficacy	I-OUTCOME
while	O
minimizing	O
changes	B-OUTCOME
in	I-OUTCOME
spine	I-OUTCOME
density	I-OUTCOME
or	O
other	O
potential	O
side	B-OUTCOME
effects	I-OUTCOME
,	O
or	O
(	O
2	O
)	O
if	O
more	O
complex	O
dose	O
–	O
response	O
relationships	O
(	O
e.g.	O
,	O
U	O
-	O
shaped	O
)	O
are	O
operative	O
.	O
Future	O
studies	O
examining	O
dose	B-OUTCOME
–	I-OUTCOME
response	I-OUTCOME
effects	I-OUTCOME
and	O
the	O
impact	O
of	O
different	O
dosing	O
schedules	O
are	O
certainly	O
warranted	O
Despite	O
the	O
potential	O
risks	O
associated	O
with	O
psychedelic	B-DRUG
microdosing	I-DRUG
,	O
the	O
data	O
presented	O
here	O
suggest	O
several	O
exciting	O
possibilities	O
for	O
the	O
treatment	O
of	O
mood	B-HEALTH CONDITION
and	I-HEALTH CONDITION
anxiety	I-HEALTH CONDITION
disorders	I-HEALTH CONDITION
.	O
First	O
,	O
a	O
chronic	O
intermittent	O
dosing	O
regimen	O
lends	O
itself	O
to	O
the	O
potential	O
prophylactic	O
treatment	O
of	O
neuropsychiatric	B-HEALTH CONDITION
diseases	I-HEALTH CONDITION
.	O
As	O
acute	O
doses	O
of	O
serotonergic	O
psychedelics	B-DRUG
produce	O
similar	O
effects	O
as	O
an	O
acute	O
dose	O
of	O
the	O
psychoplastogen	O
ketamine	B-DRUG
,	O
and	O
ketamine	B-DRUG
has	O
demonstrated	O
promise	O
for	O
preventing	B-OUTCOME
stress	I-OUTCOME
-	I-OUTCOME
induced	I-OUTCOME
depression-	I-OUTCOME
and	I-OUTCOME
anxiety	I-OUTCOME
-	O
related	O
phenotypes	O
in	O
animal	O
models	O
,	O
(	O
64−66	O
)	O
it	O
will	O
be	O
interesting	O
to	O
see	O
if	O
psychedelic	B-DRUG
microdosing	I-DRUG
is	O
also	O
capable	O
of	O
preventing	O
the	O
development	O
of	O
depression	B-HEALTH CONDITION
and	O
anxiety	B-HEALTH CONDITION
symptoms	O
.	O
Second	O
,	O
the	O
ability	O
of	O
low	O
doses	O
of	O
DMT	B-DRUG
to	O
produce	O
positive	O
effects	B-OUTCOME
on	I-OUTCOME
mood	I-OUTCOME
and	I-OUTCOME
anxiety	I-OUTCOME
in	O
rats	O
suggests	O
that	O
the	O
perceptual	B-OUTCOME
effects	I-OUTCOME
of	O
psychedelics	B-DRUG
can	O
be	O
decoupled	O
from	O
rats	O
therapeutic	B-OUTCOME
properties	I-OUTCOME
.	O
This	O
could	O
lead	O
to	O
the	O
development	O
of	O
nonhallucinogenic	B-DRUG
psychoplastogens	I-DRUG
with	O
broad	O
therapeutic	B-OUTCOME
potential	I-OUTCOME
and	O
minimal	B-OUTCOME
risk	I-OUTCOME
for	I-OUTCOME
abuse	I-OUTCOME
.	O
Taken	O
together	O
,	O
our	O
results	O
encourage	O
cautious	O
optimism	O
about	O
the	O
potential	O
for	O
psychedelic	B-DRUG
microdosing	I-DRUG
to	O
produce	O
beneficial	O
effects	O
on	O
depression	B-HEALTH CONDITION
and	O
anxiety	B-HEALTH CONDITION
-DOCSTART- -X- O O
Although	O
preliminary	O
,	O
the	O
foregoing	O
experimental	O
observations	O
make	O
a	O
case	O
that	O
some	O
subjective	B-OUTCOME
effects	I-OUTCOME
occasioned	O
by	O
moderate	O
to	O
high	O
doses	O
of	O
psychedelics	B-DRUG
play	O
a	O
key	O
role	O
in	O
high	O
doses	O
of	O
psychedelics	B-DRUG
enduring	B-OUTCOME
beneficial	I-OUTCOME
effects	I-OUTCOME
.	O
It	O
is	O
our	O
contention	O
that	O
the	O
only	O
definitive	O
study	O
to	O
disprove	O
the	O
importance	O
of	O
such	O
subjective	B-OUTCOME
effects	I-OUTCOME
would	O
be	O
one	O
in	O
which	O
a	O
psychedelic	B-DRUG
was	O
administered	O
to	O
individuals	O
who	O
were	O
rendered	O
fully	O
unconscious	B-SUBJECTIVE EXPERIENCE
(	O
e.g.	O
,	O
via	O
deep	O
anesthesia	O
)	O
and	O
who	O
subsequently	O
reported	O
no	B-OUTCOME
memory	I-OUTCOME
for	I-OUTCOME
a	I-OUTCOME
psychedelic	I-OUTCOME
-	I-OUTCOME
like	I-OUTCOME
experience	I-OUTCOME
.	O
Although	O
our	O
think	O
it	O
to	O
be	O
highly	O
unlikely	O
,	O
if	O
full	O
and	O
lasting	B-OUTCOME
therapeutic	I-OUTCOME
efficacy	I-OUTCOME
remained	O
under	O
these	O
conditions	O
,	O
we	O
would	O
concede	O
that	O
the	O
subjective	B-OUTCOME
effects	I-OUTCOME
are	O
irrelevant	O
.	O
-DOCSTART- -X- O O
Our	O
shared	O
interest	O
in	O
the	O
development	O
of	O
psychedelics	B-DRUG
,	O
and	O
particularly	O
psilocybin	B-DRUG
,	O
for	O
medical	O
use	O
is	O
a	O
major	O
point	O
of	O
convergence	O
.	O
There	O
may	O
be	O
a	O
subtle	O
difference	O
in	O
Our	O
views	O
of	O
the	O
so	O
-	O
called	O
‘	O
mystical	B-SUBJECTIVE EXPERIENCE
’	I-SUBJECTIVE EXPERIENCE
elements	I-SUBJECTIVE EXPERIENCE
of	O
the	O
psychedelic	B-SUBJECTIVE EXPERIENCE
experience	I-SUBJECTIVE EXPERIENCE
,	O
ie	O
,	O
both	O
of	O
us	O
see	O
the	O
term	O
‘	O
mystical	O
’	O
as	O
problematic	O
—	O
but	O
whereas	O
GMG	O
views	O
the	O
acute	O
‘	O
psychedelic	B-SUBJECTIVE EXPERIENCE
experience	I-SUBJECTIVE EXPERIENCE
’	O
as	O
irrelevant	O
to	O
the	O
clinical	O
development	O
of	O
psychedelics	B-DRUG
,	O
RLC	O
-	O
H	O
sees	O
RLC	O
-	O
H	O
as	O
a	O
potentially	O
exploitable	B-OUTCOME
component	I-OUTCOME
—	O
especially	O
as	O
RLC	O
-	O
H	O
has	O
been	O
shown	O
to	O
be	O
predictive	O
of	O
long	B-OUTCOME
-	I-OUTCOME
term	I-OUTCOME
clinical	I-OUTCOME
outcomes	I-OUTCOME
(	O
eg	O
,	O
in	O
Johnson	O
et	O
al	O
,	O
2014	O
;	O
Bogenschutz	O
et	O
al	O
,	O
2015	O
;	O
Griffiths	O
et	O
al	O
,	O
2016	O
;	O
Ross	O
et	O
al	O
,	O
2016	O
;	O
Carhart	O
-	O
Harris	O
et	O
al	O
,	O
2016a	O
,	O
b	O
)	O
.	O
Perhaps	O
the	O
most	O
notable	O
point	O
of	O
divergence	O
,	O
however	O
,	O
relates	O
to	O
the	O
choice	O
of	O
patient	O
population	O
for	O
the	O
clinical	O
development	O
of	O
psilocybin	B-DRUG
for	O
depression	B-HEALTH CONDITION
.	O
For	O
GMG	O
,	O
the	O
most	O
obvious	O
and	O
relevant	O
unmet	O
need	O
is	O
treatment	B-HEALTH CONDITION
-	I-HEALTH CONDITION
resistant	I-HEALTH CONDITION
depression	I-HEALTH CONDITION
(	O
see	O
below	O
)	O
,	O
and	O
while	O
RLC	O
-	O
H	O
accepts	O
that	O
treatment	B-OUTCOME
resistance	I-OUTCOME
is	O
often	O
the	O
first	O
port	O
-	O
of	O
-	O
call	O
for	O
the	O
development	O
of	O
a	O
novel	O
intervention	O
,	O
RLC	O
-	O
H	O
accepts	O
that	O
treatment	B-OUTCOME
resistance	I-OUTCOME
is	O
often	O
the	O
first	O
port	O
-	O
of	O
-	O
call	O
for	O
the	O
development	O
of	O
a	O
novel	O
intervention	O
feels	O
that	O
unipolar	B-HEALTH CONDITION
depression	I-HEALTH CONDITION
more	O
generally	O
,	O
will	O
prove	O
a	O
better	O
indication	O
for	O
this	O
treatment	O
.	O
In	O
RLC	O
-	O
H	O
accepts	O
that	O
treatment	B-OUTCOME
resistance	I-OUTCOME
is	O
often	O
the	O
first	O
port	O
-	O
of	O
-	O
call	O
for	O
the	O
development	O
of	O
a	O
novel	O
intervention	O
view	O
,	O
psilocybin	B-DRUG
will	O
be	O
safest	B-OUTCOME
,	I-OUTCOME
most	I-OUTCOME
effective	I-OUTCOME
,	I-OUTCOME
and	I-OUTCOME
easiest	I-OUTCOME
to	I-OUTCOME
implement	I-OUTCOME
,	O
prior	O
to	O
the	O
treatment	O
-	O
resistant	O
stage	O
of	O
illness	O
Focusing	O
on	O
treatment	B-HEALTH CONDITION
-	I-HEALTH CONDITION
resistant	I-HEALTH CONDITION
depression	I-HEALTH CONDITION
for	O
the	O
moment	O
,	O
however	O
,	O
we	O
both	O
recognize	O
that	O
a	O
significant	O
number	O
of	O
patients	O
treated	O
first	O
line	O
with	O
either	O
a	O
SSRI	B-ANTIDEPRESSANT DRUG
or	O
CBT	O
fail	B-OUTCOME
to	I-OUTCOME
respond	I-OUTCOME
adequately	I-OUTCOME
(	O
Gaynes	O
,	O
2009	O
)	O
.	O
Persisting	B-OUTCOME
symptoms	I-OUTCOME
lead	O
to	O
enduring	O
chronicity	O
of	O
depression	B-HEALTH CONDITION
,	O
and	O
there	O
is	O
no	O
consensus	O
in	O
existing	O
guidelines	O
on	O
what	O
to	O
do	O
next	O
.	O
Moreover	O
,	O
the	O
efficacy	B-OUTCOME
of	I-OUTCOME
secondary	I-OUTCOME
intervention	I-OUTCOME
is	I-OUTCOME
often	I-OUTCOME
modest	I-OUTCOME
and	O
new	O
medications	O
can	O
introduce	O
new	B-OUTCOME
side	I-OUTCOME
effects	I-OUTCOME
.	O
The	O
duration	O
of	O
distress	O
with	O
TRD	B-HEALTH CONDITION
and	O
its	O
economic	O
impact	O
are	O
considerable	O
.	O
We	O
agree	O
that	O
TRD	B-HEALTH CONDITION
represents	O
a	O
valid	O
point	O
in	O
the	O
treatment	O
pathway	O
,	O
where	O
a	O
single	O
psychedelic	B-DRUG
intervention	O
might	O
find	O
a	O
place	O
;	O
however	O
,	O
RLC	O
-	O
H	O
questions	O
whether	O
patients	O
must	O
wait	O
until	O
patients	O
depression	B-HEALTH CONDITION
is	O
significantly	O
stamped	O
-	O
in	O
before	O
psilocybin	B-DRUG
can	O
be	O
considered	O
,	O
and	O
based	O
on	O
the	O
speed	B-OUTCOME
and	I-OUTCOME
duration	I-OUTCOME
of	I-OUTCOME
treatment	I-OUTCOME
responses	I-OUTCOME
seen	O
in	O
the	O
trials	O
listed	O
above	O
,	O
it	O
seems	O
reasonable	O
to	O
ask	O
whether	O
early	O
intervention	O
with	O
psilocybin	B-DRUG
could	O
be	O
prophylactic	O
—	O
and	O
there	O
is	O
also	O
the	O
issue	O
of	O
SSRIs	B-ANTIDEPRESSANT DRUG
obstructing	O
the	O
potential	B-OUTCOME
therapeutic	I-OUTCOME
action	I-OUTCOME
of	I-OUTCOME
psilocybin	I-OUTCOME
If	O
it	O
is	O
to	O
be	O
TRD	B-HEALTH CONDITION
,	O
however	O
,	O
then	O
patient	O
recruitment	O
can	O
be	O
based	O
on	O
pre	O
-	O
existing	O
criteria	O
(	O
Sackeim	O
,	O
2001	O
)	O
and	O
patients	O
meeting	O
patients	O
will	O
not	O
be	O
rare	O
and	O
should	O
not	O
be	O
excessively	O
treatment	O
resistant	O
.	O
As	O
noted	O
earlier	O
,	O
there	O
is	O
a	O
significant	O
challenge	O
to	O
the	O
issue	O
of	O
continuing	O
medication	O
,	O
most	O
commonly	O
with	O
SSRIs	B-ANTIDEPRESSANT DRUG
.	O
There	O
is	O
anecdotal	O
evidence	O
that	O
psychedelic	B-OUTCOME
effects	I-OUTCOME
are	O
largely	O
attenuated	O
by	O
ongoing	O
treatment	O
with	O
SSRIs	B-ANTIDEPRESSANT DRUG
(	O
Bonson	O
et	O
al	O
,	O
1996	O
)	O
and	O
perhaps	O
with	O
other	O
antidepressants	B-ANTIDEPRESSANT DRUG
(	O
Bonson	O
and	O
Murphy	O
,	O
1996	O
)	O
.	O
Downregulation	O
of	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptors	I-NEURAL MECHANISM/CORRELATE
is	O
a	O
feature	O
of	O
many	O
different	O
first	O
-	O
line	O
antidepressant	B-ANTIDEPRESSANT DRUG
drugs	I-ANTIDEPRESSANT DRUG
(	O
Muguruza	O
et	O
al	O
,	O
2014	O
)	O
,	O
as	O
well	O
as	O
second	O
-	O
line	O
antidepressant	B-ANTIDEPRESSANT DRUG
medications	I-ANTIDEPRESSANT DRUG
(	O
eg	O
,	O
atypical	O
antipsychotics	O
)	O
with	O
significant	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2AR	I-NEURAL MECHANISM/CORRELATE
antagonist	I-NEURAL MECHANISM/CORRELATE
properties	I-NEURAL MECHANISM/CORRELATE
(	O
Gray	O
and	O
Roth	O
,	O
2001	O
)	O
.	O
Any	O
trial	O
would	O
ideally	O
be	O
conducted	O
in	O
patients	O
withdrawn	O
from	O
such	O
drugs	O
for	O
at	O
least	O
2	O
weeks	O
or	O
so	O
,	O
but	O
we	O
accept	O
that	O
this	O
is	O
not	O
always	O
straightforward	O
Moving	O
on	O
from	O
questions	O
of	O
the	O
optimal	O
patient	O
population	O
,	O
both	O
of	O
us	O
can	O
see	O
merit	O
in	O
a	O
multiple	O
dose	O
trial	O
comparing	O
,	O
for	O
example	O
,	O
1	O
,	O
10	O
and	O
25	O
mg	O
of	O
psilocybin	B-DRUG
.	O
Such	O
a	O
design	O
seems	O
to	O
overcome	O
some	O
of	O
the	O
problems	B-OUTCOME
any	O
trial	O
of	O
a	O
psychedelic	O
will	O
face	O
.	O
The	O
ethical	B-OUTCOME
problem	I-OUTCOME
of	O
equipoise	O
seems	O
satisfactory	O
because	O
we	O
really	O
do	O
not	O
know	O
which	O
dose	O
,	O
if	O
any	O
,	O
will	O
be	O
effective	O
,	O
and	O
patients	O
can	O
enter	O
the	O
study	O
knowing	O
that	O
whatever	O
group	O
patients	O
are	O
allocated	O
to	O
,	O
patients	O
will	O
receive	O
active	O
drug	B-DRUG
.	O
The	O
omission	O
of	O
a	O
strict	O
placebo	O
control	O
would	O
be	O
pragmatic	O
in	O
this	O
sense	O
,	O
as	O
expectation	O
and	O
preparation	O
would	O
be	O
standardized	O
.	O
We	O
know	O
the	O
highest	O
dose	O
of	O
psilocybin	B-DRUG
will	O
likely	O
unblind	O
participants	O
and	O
the	O
expectation	O
of	O
a	O
possible	O
placebo	O
would	O
complicate	O
recruitment	O
.	O
An	O
approximation	O
to	O
an	O
inert	O
placebo	O
condition	O
may	O
be	O
met	O
with	O
the	O
1	O
mg	O
psilocybin	B-DRUG
arm	O
,	O
as	O
such	O
a	O
dose	O
is	O
likely	O
too	O
low	O
to	O
produce	O
appreciable	O
subjective	B-OUTCOME
or	I-OUTCOME
physiological	I-OUTCOME
effects	I-OUTCOME
(	O
Griffiths	O
et	O
al	O
,	O
2016	O
)	O
.	O
The	O
differences	O
between	O
a	O
dose	O
mainly	O
producing	O
perceptual	B-OUTCOME
distortion	I-OUTCOME
(	O
10	O
mg	O
)	O
and	O
one	O
more	O
capable	O
of	O
producing	O
the	O
more	O
profound	O
,	O
putatively	B-OUTCOME
‘	I-OUTCOME
transformative	I-OUTCOME
’	I-OUTCOME
aspects	I-OUTCOME
of	O
the	O
psychedelic	O
experience	O
(	O
25	O
mg	O
)	O
is	O
also	O
of	O
scientific	O
and	O
clinical	O
interest	O
Comparing	O
mechanisms	O
and/or	O
efficacy	B-OUTCOME
with	O
an	O
established	O
treatment	O
would	O
be	O
a	O
next	O
step	O
to	O
advance	O
the	O
evidence	O
base	O
for	O
psilocybin	B-DRUG
for	O
TRD	B-HEALTH CONDITION
.	O
For	O
example	O
,	O
psilocybin	B-DRUG
could	O
be	O
compared	O
with	O
ketamine	B-DRUG
since	O
it	O
has	O
some	O
similarities	O
:	O
rapid	B-OUTCOME
,	I-OUTCOME
single	I-OUTCOME
-	I-OUTCOME
dose	I-OUTCOME
efficacy	I-OUTCOME
,	O
and	O
obvious	O
subjective	B-OUTCOME
effects	I-OUTCOME
during	O
it	O
infusion	O
.	O
Psilocybin	B-DRUG
’s	O
distinctive	O
subjective	B-OUTCOME
effects	I-OUTCOME
and	O
the	O
implications	O
of	O
this	O
for	O
blinding	O
would	O
still	O
remain	O
a	O
major	O
challenge	O
;	O
moreover	O
,	O
as	O
with	O
ketamine	B-DRUG
,	O
there	O
will	O
also	O
remain	O
the	O
question	O
of	O
how	O
much	O
an	O
acute	O
response	O
is	O
sustained	O
and	O
whether	O
a	O
maintenance	O
dose	O
may	O
be	O
required	O
The	O
traditional	O
view	O
of	O
the	O
mechanism	O
,	O
whereby	O
psilocybin	B-DRUG
works	O
,	O
emphasizes	O
the	O
importance	O
of	O
accompanying	O
psychotherapy	O
(	O
Johnson	O
et	O
al	O
,	O
2008	O
;	O
Richards	O
,	O
2015	O
)	O
.	O
Accordingly	O
,	O
psychedelics	B-DRUG
administered	I-DRUG
without	I-DRUG
psychological	I-DRUG
support	I-DRUG
and/or	O
a	O
supportive	O
environment	O
may	O
have	O
limited	B-OUTCOME
antidepressant	I-OUTCOME
efficacy	I-OUTCOME
,	O
and	O
in	O
very	O
rare	O
cases	O
,	O
could	O
even	O
worsen	B-OUTCOME
a	I-OUTCOME
patient	I-OUTCOME
’s	I-OUTCOME
condition	I-OUTCOME
(	O
Oram	O
,	O
2014	O
)	O
.	O
We	O
share	O
the	O
view	O
that	O
the	O
presence	O
of	O
psychological	O
support	O
is	O
an	O
essential	O
component	O
of	O
the	O
psychedelic	O
treatment	O
model	O
(	O
Johnson	O
et	O
al	O
,	O
2008	O
)	O
but	O
We	O
also	O
recognize	O
that	O
the	O
magnitude	O
and	O
nature	O
of	O
its	O
contribution	O
needs	O
to	O
be	O
better	O
defined	O
and	O
tested	O
Pragmatically	O
,	O
We	O
accept	O
that	O
minimizing	O
the	O
active	O
psychological	O
work	O
of	O
the	O
therapy	O
would	O
be	O
desirable	O
(	O
eg	O
,	O
therapy	O
time	O
is	O
expensive	O
)	O
and	O
scientifically	O
,	O
doing	O
so	O
would	O
allow	O
drug	B-OUTCOME
effects	I-OUTCOME
and	O
dose	O
to	O
be	O
better	O
identified	O
.	O
Critically	O
however	O
,	O
any	O
such	O
therapy	O
minimization	O
should	O
not	O
be	O
allowed	O
to	O
jeopardize	O
patient	O
safety	O
(	O
Johnson	O
et	O
al	O
,	O
2008	O
)	O
.	O
A	O
future	O
challenge	O
will	O
be	O
to	O
learn	O
how	O
psychological	O
interventions	O
can	O
maximize	O
the	O
advantages	O
of	O
the	O
psychedelic	B-SUBJECTIVE EXPERIENCE
state	I-SUBJECTIVE EXPERIENCE
.	O
For	O
example	O
,	O
we	O
can	O
imagine	O
how	O
cognitive	O
therapy	O
,	O
attentional	O
-	O
bias	O
training	O
and/or	O
de	O
-	O
sensitization	O
could	O
be	O
investigated	O
with	O
or	O
without	O
psilocybin	B-DRUG
assistance	O
In	O
other	O
respects	O
,	O
a	O
psilocybin	B-DRUG
trial	O
is	O
easier	O
to	O
conduct	O
than	O
studies	O
requiring	O
continuing	O
adherence	O
to	O
a	O
daily	O
oral	O
dose	O
of	O
an	O
antidepressant	B-ANTIDEPRESSANT DRUG
.	O
Exposure	O
to	O
the	O
treatment	O
can	O
be	O
completely	O
controlled	O
and	O
follow	O
-	O
up	O
can	O
be	O
relatively	O
pragmatic	O
.	O
It	O
seems	O
logical	O
to	O
determine	O
an	O
early	O
proximal	O
end	O
point	O
to	O
prove	O
initial	O
impact	O
of	O
treatment	O
and	O
then	O
to	O
follow	O
subsequent	O
illness	O
course	O
as	O
comprehensively	O
as	O
possible	O
.	O
In	O
this	O
way	O
,	O
we	O
will	O
be	O
able	O
to	O
determine	O
time	O
to	O
supplementary	O
treatment	O
,	O
document	O
recovery	B-OUTCOME
of	I-OUTCOME
symptoms	I-OUTCOME
and	I-OUTCOME
function	I-OUTCOME
,	O
and	O
perhaps	O
objectify	O
improvement	O
using	O
a	O
simple	O
frictionless	O
measure	O
of	O
activity	O
-	O
like	O
geolocation	O
(	O
Palmius	O
et	O
al	O
,	O
2016	O
)	O
In	O
the	O
short	O
term	O
,	O
there	O
will	O
also	O
be	O
a	O
need	O
to	O
demonstrate	O
cost	O
effectiveness	O
.	O
The	O
requirement	O
for	O
psychological	O
support	O
and/or	O
a	O
supportive	O
environment	O
could	O
be	O
a	O
major	O
limitation	O
of	O
the	O
psychedelic	O
treatment	O
model	O
.	O
However	O
,	O
direct	O
medical	O
costs	O
need	O
to	O
be	O
netted	O
off	O
against	O
the	O
social	O
and	O
economic	O
costs	O
of	O
illness	O
In	O
summary	O
,	O
a	O
door	O
has	O
been	O
opened	O
for	O
the	O
medical	O
repurposing	O
of	O
psychedelics	B-DRUG
.	O
The	O
possibility	O
exists	O
that	O
drugs	O
like	O
psilocybin	B-DRUG
can	O
meet	O
a	O
major	O
unmet	O
need	O
in	O
the	O
treatment	O
of	O
psychiatric	B-HEALTH CONDITION
disorders	I-HEALTH CONDITION
.	O
For	O
GMG	O
,	O
treatment	B-HEALTH CONDITION
-	I-HEALTH CONDITION
resistant	I-HEALTH CONDITION
depression	I-HEALTH CONDITION
is	O
the	O
most	O
logical	O
place	O
to	O
start	O
because	O
of	O
the	O
uncertainty	O
around	O
the	O
choice	O
of	O
next	O
-	O
step	O
treatment	O
after	O
an	O
SSRI	B-ANTIDEPRESSANT DRUG
fails	O
,	O
and	O
while	O
RLC	O
-	O
H	O
accepts	O
this	O
(	O
Carhart	O
-	O
Harris	O
et	O
al	O
,	O
2016a	O
,	O
b	O
)	O
,	O
RLC	O
-	O
H	O
accepts	O
this	O
(	O
Carhart	O
-	O
Harris	O
et	O
al	O
,	O
2016a	O
,	O
b	O
)	O
looks	O
forward	O
to	O
a	O
time	O
when	O
an	O
individual	O
may	O
receive	O
psilocybin	B-DRUG
before	O
the	O
ruts	O
of	O
depression	B-HEALTH CONDITION
are	O
allowed	O
to	O
deepen	O
(	O
Holtzheimer	O
and	O
Mayberg	O
,	O
2011	O
)	O
.	O
Regardless	O
of	O
who	O
the	O
‘	O
right	O
’	O
patient	O
population	O
might	O
be	O
eventually	O
,	O
a	O
key	O
challenge	O
now	O
is	O
to	O
design	O
the	O
optimal	O
trial	O
to	O
demonstrate	O
efficacy	B-OUTCOME
,	O
agree	O
a	O
key	O
challenge	O
validity	O
with	O
regulatory	O
authorities	O
and	O
fund	O
a	O
key	O
challenge	O
.	O
-DOCSTART- -X- O O
When	O
administered	O
under	O
psychologically	O
supportive	O
,	O
double	O
-	O
blind	O
conditions	O
,	O
a	O
single	O
dose	O
of	O
psilocybin	B-DRUG
produced	O
substantial	O
and	O
enduring	O
decreases	O
in	O
depressed	B-HEALTH CONDITION
mood	I-HEALTH CONDITION
and	O
anxiety	B-HEALTH CONDITION
along	O
with	O
increases	O
in	O
quality	B-OUTCOME
of	I-OUTCOME
life	I-OUTCOME
and	O
decreases	O
in	O
death	B-HEALTH CONDITION
anxiety	I-HEALTH CONDITION
in	O
patients	O
with	O
a	O
life	B-HEALTH CONDITION
-	I-HEALTH CONDITION
threatening	I-HEALTH CONDITION
cancer	I-HEALTH CONDITION
diagnosis	O
.	O
Ratings	O
by	O
patients	O
themselves	O
,	O
clinicians	O
,	O
and	O
community	O
observers	O
suggested	O
these	O
effects	B-OUTCOME
endured	I-OUTCOME
at	I-OUTCOME
least	I-OUTCOME
6	I-OUTCOME
months	I-OUTCOME
.	O
The	O
overall	O
rate	O
of	O
clinical	O
response	O
at	O
6	O
months	O
on	O
clinician	O
-	O
rated	O
depression	B-HEALTH CONDITION
and	O
anxiety	B-HEALTH CONDITION
was	O
78	O
%	O
and	O
83	O
%	O
,	O
respectively	O
.	O
A	O
multisite	O
study	O
in	O
a	O
larger	O
and	O
more	O
diverse	O
patient	O
population	O
should	O
be	O
conducted	O
to	O
establish	O
the	O
generality	O
and	O
safety	O
of	O
psilocybin	B-DRUG
treatment	O
of	O
psychological	B-HEALTH CONDITION
distress	I-HEALTH CONDITION
associated	O
with	O
life	B-HEALTH CONDITION
-	I-HEALTH CONDITION
threatening	I-HEALTH CONDITION
cancer	I-HEALTH CONDITION
.	O
-DOCSTART- -X- O O
In	O
conclusion	O
,	O
single	O
moderate	O
-	O
dose	O
psilocybin	B-DRUG
(	O
in	O
conjunction	O
with	O
psychotherapy	O
)	O
was	O
safely	O
administered	O
to	O
a	O
cohort	O
of	O
patients	O
with	O
cancer	B-HEALTH CONDITION
-	I-HEALTH CONDITION
related	I-HEALTH CONDITION
psychological	I-HEALTH CONDITION
distress	I-HEALTH CONDITION
(	O
e.g.	O
anxiety	B-HEALTH CONDITION
,	O
depression	B-HEALTH CONDITION
)	O
.	O
It	O
produced	O
rapid	B-OUTCOME
and	I-OUTCOME
sustained	I-OUTCOME
anxiolytic	I-OUTCOME
and	I-OUTCOME
anti	I-OUTCOME
-	I-OUTCOME
depressant	I-OUTCOME
effects	I-OUTCOME
(	O
for	O
at	O
least	O
7	O
weeks	O
but	O
potentially	O
as	O
long	O
as	O
8	O
months	O
)	O
,	O
decreased	B-OUTCOME
cancer	I-OUTCOME
-	I-OUTCOME
related	I-OUTCOME
existential	I-OUTCOME
distress	I-OUTCOME
,	O
increased	O
spiritual	B-OUTCOME
wellbeing	I-OUTCOME
and	O
quality	B-OUTCOME
of	I-OUTCOME
life	I-OUTCOME
,	O
and	O
was	O
associated	O
with	O
improved	O
attitudes	B-OUTCOME
towards	I-OUTCOME
death	I-OUTCOME
.	O
The	O
psilocybin	B-DRUG
-	O
induced	O
mystical	B-SUBJECTIVE EXPERIENCE
experience	I-SUBJECTIVE EXPERIENCE
mediated	O
the	O
anxiolytic	B-OUTCOME
and	I-OUTCOME
anti	I-OUTCOME
-	I-OUTCOME
depressant	I-OUTCOME
effects	I-OUTCOME
of	O
psilocybin	B-DRUG
.	O
Psilocybin	B-DRUG
,	O
administered	O
in	O
conjunction	O
with	O
appropriate	O
psychotherapy	O
,	O
could	O
become	O
a	O
novel	O
pharmacological	O
-	O
psychosocial	O
treatment	O
modality	O
for	O
cancer	B-HEALTH CONDITION
-	I-HEALTH CONDITION
related	I-HEALTH CONDITION
psychological	I-HEALTH CONDITION
and	I-HEALTH CONDITION
existential	I-HEALTH CONDITION
distress	I-HEALTH CONDITION
.	O
Further	O
empirical	O
research	O
is	O
needed	O
definitively	O
to	O
establish	O
Further	O
empirical	O
research	O
safety	B-OUTCOME
and	I-OUTCOME
efficacy	I-OUTCOME
.	O
-DOCSTART- -X- O O
This	O
article	O
has	O
argued	O
that	O
scientific	O
research	O
with	O
psychedelic	B-DRUG
drugs	I-DRUG
can	O
have	O
a	O
revitalizing	B-OUTCOME
effect	I-OUTCOME
on	I-OUTCOME
psychoanalysis	I-OUTCOME
and	O
an	O
informing	O
influence	B-OUTCOME
on	I-OUTCOME
mainstream	I-OUTCOME
psychology	I-OUTCOME
and	I-OUTCOME
psychiatry	I-OUTCOME
.	O
Rather	O
than	O
discuss	O
the	O
content	O
and	O
interpretation	O
of	O
psychoanalytically	O
-	O
relevant	O
material	O
,	O
we	O
have	O
adopted	O
a	O
mechanistic	O
approach	O
,	O
in	O
keeping	O
with	O
the	O
mainstream	O
cognitive	O
neuroscience	O
.	O
This	O
article	O
proposes	O
that	O
a	O
distinction	O
can	O
be	O
made	O
between	O
two	O
fundamentally	O
different	O
modes	O
of	O
cognition	B-SUBJECTIVE EXPERIENCE
:	O
primary	O
and	O
secondary	O
consciousness	B-SUBJECTIVE EXPERIENCE
.	O
Primary	B-SUBJECTIVE EXPERIENCE
consciousness	I-SUBJECTIVE EXPERIENCE
is	O
associated	O
with	O
unconstrained	B-OUTCOME
cognition	I-OUTCOME
and	I-OUTCOME
less	I-OUTCOME
ordered	I-OUTCOME
(	I-OUTCOME
higher	I-OUTCOME
-	I-OUTCOME
entropy	I-OUTCOME
)	I-OUTCOME
neurodynamics	I-OUTCOME
,	O
whereas	O
secondary	B-SUBJECTIVE EXPERIENCE
consciousness	I-SUBJECTIVE EXPERIENCE
is	O
associated	O
with	O
constrained	B-OUTCOME
cognition	I-OUTCOME
and	I-OUTCOME
more	I-OUTCOME
ordered	I-OUTCOME
neurodynamics	I-OUTCOME
(	O
i.e.	O
,	O
that	O
strikes	O
an	O
evolutionarily	O
advantageous	O
balance	O
between	O
order	O
and	O
disorder	O
-	O
that	O
may	O
or	O
more	O
not	O
be	O
perfectly	O
“	O
critical	O
”	O
)	O
.	O
It	O
is	O
hoped	O
that	O
this	O
mechanistic	O
model	O
will	O
help	O
catalyze	O
a	O
synthesis	O
between	O
psychoanalytic	O
theory	O
and	O
cognitive	O
neuroscience	O
that	O
can	O
be	O
mutually	B-OUTCOME
beneficial	I-OUTCOME
to	O
both	O
disciplines	O
.	O
It	O
is	O
a	O
fair	O
criticism	O
of	O
this	O
paper	O
that	O
this	O
paper	O
has	O
given	O
insufficient	B-OUTCOME
consideration	I-OUTCOME
to	I-OUTCOME
the	I-OUTCOME
phenomenological	I-OUTCOME
content	I-OUTCOME
of	O
the	O
relevant	O
altered	B-SUBJECTIVE EXPERIENCE
states	I-SUBJECTIVE EXPERIENCE
of	I-SUBJECTIVE EXPERIENCE
consciousness	I-SUBJECTIVE EXPERIENCE
,	O
and	O
to	O
the	O
specifics	O
of	O
Freudian	O
theory	O
,	O
and	O
so	O
by	O
neglecting	O
this	O
,	O
has	O
failed	B-OUTCOME
to	I-OUTCOME
present	I-OUTCOME
a	I-OUTCOME
sufficiently	I-OUTCOME
compelling	I-OUTCOME
case	I-OUTCOME
that	O
these	O
states	O
have	O
anything	O
to	O
do	O
with	O
psychoanalytic	O
theory	O
.	O
To	O
some	O
extent	O
,	O
this	O
charge	O
can	O
be	O
conceded	O
;	O
however	O
,	O
as	O
outlined	O
in	O
the	O
introduction	O
,	O
the	O
intention	O
of	O
this	O
paper	O
was	O
to	O
develop	O
a	O
mechanistic	O
account	O
of	O
altered	B-SUBJECTIVE EXPERIENCE
states	I-SUBJECTIVE EXPERIENCE
of	I-SUBJECTIVE EXPERIENCE
consciousness	I-SUBJECTIVE EXPERIENCE
based	O
on	O
the	O
quantity	B-NEURAL MECHANISM/CORRELATE
of	I-NEURAL MECHANISM/CORRELATE
entropy	I-NEURAL MECHANISM/CORRELATE
,	O
and	O
this	O
task	O
has	O
demanded	O
a	O
substantial	O
amount	O
of	O
space	O
.	O
A	O
more	O
thorough	O
discussion	O
of	O
the	O
phenomenology	B-SUBJECTIVE EXPERIENCE
of	I-SUBJECTIVE EXPERIENCE
primary	I-SUBJECTIVE EXPERIENCE
states	I-SUBJECTIVE EXPERIENCE
is	O
required	O
to	O
develop	O
the	O
case	O
that	O
primary	B-SUBJECTIVE EXPERIENCE
states	I-SUBJECTIVE EXPERIENCE
show	O
characteristics	B-OUTCOME
that	I-OUTCOME
are	I-OUTCOME
consistent	I-OUTCOME
with	I-OUTCOME
Freudian	I-OUTCOME
accounts	I-OUTCOME
of	I-OUTCOME
“	I-OUTCOME
the	I-OUTCOME
unconscious	I-OUTCOME
”	I-OUTCOME
or	I-OUTCOME
“	I-OUTCOME
Id.	I-OUTCOME
”	O
The	O
reader	O
should	O
be	O
made	O
aware	O
however	O
,	O
that	O
this	O
has	O
been	O
attempted	O
before	O
(	O
Carhart	O
-	O
Harris	O
,	O
2007	O
;	O
Carhart	O
-	O
Harris	O
and	O
Friston	O
,	O
2010	O
)	O
.	O
To	O
conclude	O
,	O
it	O
is	O
perhaps	O
not	O
surprising	O
that	O
with	O
only	O
dreaming	B-SUBJECTIVE EXPERIENCE
and	O
psychosis	B-HEALTH CONDITION
at	O
it	O
disposal	O
,	O
psychoanalysis	O
has	O
failed	O
to	O
convince	O
the	O
scientific	O
community	O
that	O
the	O
psychoanalytic	O
unconscious	O
exists	O
(	O
Hassin	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O
From	O
a	O
neuroscientific	O
perspective	O
,	O
dreaming	B-SUBJECTIVE EXPERIENCE
and	O
psychosis	B-HEALTH CONDITION
are	O
notoriously	O
difficult	O
to	O
study	O
.	O
The	O
occurrence	O
of	O
dreaming	B-SUBJECTIVE EXPERIENCE
in	O
sleep	B-SUBJECTIVE EXPERIENCE
impedes	O
experimental	O
control	O
and	O
psychosis	B-HEALTH CONDITION
is	O
an	O
especially	O
complex	O
and	O
variegated	O
phenomenon	O
.	O
However	O
,	O
for	O
those	O
brave	O
enough	O
to	O
embrace	O
it	O
,	O
research	O
with	O
psychedelics	B-DRUG
could	O
herald	O
the	O
beginning	O
of	O
a	O
new	O
scientifically	O
informed	O
-	O
psychoanalysis	O
that	O
has	O
the	O
potential	O
to	O
influence	B-OUTCOME
modern	I-OUTCOME
psychology	I-OUTCOME
and	I-OUTCOME
psychiatry	I-OUTCOME
.	O
The	O
unique	B-OUTCOME
scientific	I-OUTCOME
value	I-OUTCOME
of	O
psychedelics	B-DRUG
rests	O
in	O
their	O
capacity	B-OUTCOME
to	I-OUTCOME
make	I-OUTCOME
consciously	I-OUTCOME
accessible	I-OUTCOME
that	I-OUTCOME
which	I-OUTCOME
is	I-OUTCOME
latent	I-OUTCOME
in	I-OUTCOME
the	I-OUTCOME
mind	I-OUTCOME
.	O
This	O
paper	O
takes	O
the	O
position	O
that	O
mainstream	O
psychology	O
and	O
psychiatry	O
have	O
underappreciated	O
the	O
depth	O
of	O
the	O
human	B-NEURAL MECHANISM/CORRELATE
mind	I-NEURAL MECHANISM/CORRELATE
by	O
neglecting	O
schools	O
of	O
thought	O
that	O
posit	O
the	O
existence	O
an	O
unconscious	B-NEURAL MECHANISM/CORRELATE
mind	I-NEURAL MECHANISM/CORRELATE
.	O
Indeed	O
,	O
psychedelics	B-DRUG
'	O
greatest	O
value	O
may	O
be	O
as	O
a	O
remedy	B-OUTCOME
for	I-OUTCOME
ignorance	I-OUTCOME
of	I-OUTCOME
the	I-OUTCOME
unconscious	I-OUTCOME
mind	I-OUTCOME
.	O
-DOCSTART- -X- O O
This	O
paper	O
has	O
sought	O
to	O
address	O
a	O
major	O
unresolved	O
problem	O
in	O
neuropsychopharmacology	O
,	O
namely	O
what	O
is	O
the	O
function	O
of	O
brain	B-NEURAL MECHANISM/CORRELATE
serotonin	I-NEURAL MECHANISM/CORRELATE
?	O
This	O
paper	O
proposes	O
that	O
the	O
principal	O
function	O
of	O
brain	B-NEURAL MECHANISM/CORRELATE
serotonin	I-NEURAL MECHANISM/CORRELATE
is	O
to	O
enhance	O
adaptive	B-OUTCOME
responses	I-OUTCOME
to	I-OUTCOME
adverse	I-OUTCOME
conditions	I-OUTCOME
via	O
two	O
distinct	O
pathways	O
:	O
(	O
1	O
)	O
a	O
passive	O
coping	O
pathway	O
which	O
improves	O
stress	B-OUTCOME
tolerability	I-OUTCOME
;	O
and	O
(	O
2	O
)	O
an	O
active	O
coping	O
pathway	O
associated	O
with	O
heightened	B-OUTCOME
plasticity	I-OUTCOME
,	O
which	O
,	O
with	O
support	O
,	O
can	O
improve	O
an	O
organism	B-OUTCOME
’s	I-OUTCOME
ability	I-OUTCOME
to	I-OUTCOME
identify	I-OUTCOME
and	I-OUTCOME
overcome	I-OUTCOME
source(s	I-OUTCOME
)	I-OUTCOME
of	I-OUTCOME
stress	I-OUTCOME
by	O
changing	B-OUTCOME
outlook	I-OUTCOME
and/or	I-OUTCOME
behaviour	I-OUTCOME
.	O
Crucially	O
,	O
we	O
propose	O
that	O
these	O
two	O
functions	O
are	O
mediated	O
by	O
signalling	O
at	O
postsynaptic	B-NEURAL MECHANISM/CORRELATE
5	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT1A	I-NEURAL MECHANISM/CORRELATE
and	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptors	I-NEURAL MECHANISM/CORRELATE
respectively	O
,	O
with	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT1AR	I-NEURAL MECHANISM/CORRELATE
signalling	I-NEURAL MECHANISM/CORRELATE
dominating	O
under	O
ordinary	O
conditions	O
but	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2AR	I-NEURAL MECHANISM/CORRELATE
signalling	I-NEURAL MECHANISM/CORRELATE
becoming	O
increasingly	O
operative	O
as	O
the	O
level	O
of	O
adversity	O
reaches	O
a	O
critical	O
point	O
.	O
We	O
suggest	O
that	O
the	O
two	O
functions	O
of	O
interest	O
(	O
5	B-OUTCOME
-	I-OUTCOME
HT1AR	I-OUTCOME
-	I-OUTCOME
mediated	I-OUTCOME
stress	I-OUTCOME
relief	I-OUTCOME
and	O
5	B-OUTCOME
-	I-OUTCOME
HT2AR	I-OUTCOME
-	I-OUTCOME
mediated	I-OUTCOME
plasticity	I-OUTCOME
)	O
are	O
sufficiently	O
distinct	O
–	O
and	O
may	O
even	O
be	O
mutually	O
oppositional	O
in	O
certain	O
contexts	O
(	O
see	O
also	O
Azmitia	O
,	O
2001	O
)	O
,	O
evoking	O
dilemmas	O
over	O
whether	O
it	O
is	O
better	O
to	O
passively	O
endure	O
or	O
actively	O
approach	O
,	O
and	O
in	O
so	O
doing	O
,	O
initiate	O
some	O
sort	O
of	O
fundamental	B-OUTCOME
change	I-OUTCOME
–	I-OUTCOME
with	I-OUTCOME
the	I-OUTCOME
potential	I-OUTCOME
for	I-OUTCOME
major	I-OUTCOME
resolution	I-OUTCOME
.	O
This	O
rule	O
may	O
not	O
be	O
absolute	O
however	O
,	O
and	O
the	O
two	O
functions	O
may	O
also	O
be	O
complementary	O
,	O
e.g.	O
in	O
the	O
case	O
of	O
enhanced	B-NEURAL MECHANISM/CORRELATE
serotonin	I-NEURAL MECHANISM/CORRELATE
functioning	I-NEURAL MECHANISM/CORRELATE
with	O
chronic	O
SSRI	B-ANTIDEPRESSANT DRUG
use	O
–	O
or	O
indeed	O
with	O
normal	O
basal	B-NEURAL MECHANISM/CORRELATE
5	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT	I-NEURAL MECHANISM/CORRELATE
functioning	I-NEURAL MECHANISM/CORRELATE
,	O
facilitating	O
improved	B-OUTCOME
endurance	I-OUTCOME
and	I-OUTCOME
plasticity	I-OUTCOME
(	O
Clarke	O
et	O
al	O
.	O
,	O
2004	O
,	O
2007	O
;	O
Mithoefer	O
et	O
al	O
.	O
,	O
2011	O
,	O
2016	O
;	O
van	O
Apeldoorn	O
et	O
al	O
.	O
,	O
2008	O
)	O
Despite	O
this	O
complementarity	O
,	O
we	O
do	O
anticipate	O
that	O
conventional	O
serotonergic	B-ANTIDEPRESSANT DRUG
antidepressants	I-ANTIDEPRESSANT DRUG
such	O
as	O
the	O
SSRIs	B-ANTIDEPRESSANT DRUG
and	O
classic	O
psychedelics	B-DRUG
such	O
as	O
psilocybin	B-DRUG
may	O
become	O
competitive	O
options	O
for	O
the	O
treatments	O
of	O
certain	O
disorders	O
such	O
as	O
depression	B-HEALTH CONDITION
;	O
most	O
fundamentally	O
because	O
conventional	O
serotonergic	B-ANTIDEPRESSANT DRUG
antidepressants	I-ANTIDEPRESSANT DRUG
such	O
as	O
the	O
SSRIs	B-ANTIDEPRESSANT DRUG
and	O
classic	O
psychedelics	B-DRUG
such	O
as	O
psilocybin	B-DRUG
may	O
become	O
competitive	B-OUTCOME
options	I-OUTCOME
for	O
the	O
treatments	O
of	O
certain	O
disorders	O
such	O
as	O
depression	B-HEALTH CONDITION
work	O
via	O
distinct	O
pathways	O
(	O
i.e.	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT1AR	I-NEURAL MECHANISM/CORRELATE
versus	O
the	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2AR	I-NEURAL MECHANISM/CORRELATE
signalling	O
)	O
–	O
but	O
also	O
because	O
conventional	O
serotonergic	B-ANTIDEPRESSANT DRUG
antidepressants	I-ANTIDEPRESSANT DRUG
such	O
as	O
the	O
SSRIs	B-ANTIDEPRESSANT DRUG
and	O
classic	O
psychedelics	B-DRUG
such	O
as	O
psilocybin	B-DRUG
may	O
become	O
competitive	O
options	O
for	O
the	O
treatments	O
of	O
certain	O
disorders	O
such	O
as	O
depression	B-HEALTH CONDITION
can	O
not	O
easily	O
be	O
taken	O
in	O
combination	O
,	O
i.e.	O
conventional	O
antidepressants	B-ANTIDEPRESSANT DRUG
attenuate	B-OUTCOME
the	I-OUTCOME
characteristic	I-OUTCOME
psychological	I-OUTCOME
effects	I-OUTCOME
of	I-OUTCOME
psychedelics	I-OUTCOME
(	O
Bonson	O
et	O
al	O
.	O
,	O
1996	O
;	O
Bonson	O
and	O
Murphy	O
,	O
1996	O
)	O
.	O
SSRIs	B-ANTIDEPRESSANT DRUG
are	O
established	O
evidence	O
-	O
based	O
treatments	O
for	O
anxiety	B-HEALTH CONDITION
and	O
major	B-HEALTH CONDITION
depression	I-HEALTH CONDITION
(	O
Baldwin	O
et	O
al	O
.	O
,	O
2016	O
;	O
Hieronymus	O
et	O
al	O
.	O
,	O
2016	O
)	O
,	O
whereas	O
psychedelics	B-DRUG
are	O
experimental	O
medicines	O
in	O
an	O
early	O
phase	O
of	O
development	O
(	O
Carhart	O
-	O
Harris	O
and	O
Goodwin	O
,	O
2017	O
;	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
However	O
,	O
if	O
evidence	O
supporting	O
the	O
therapeutic	B-OUTCOME
value	I-OUTCOME
of	O
psychedelics	B-DRUG
accrues	O
–	O
as	O
we	O
anticipate	O
,	O
and	O
it	O
is	O
increasingly	O
shown	O
that	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
,	O
2016	O
)	O
therapeutic	B-OUTCOME
mechanisms	I-OUTCOME
are	O
significantly	O
distinct	O
from	O
those	O
of	O
conventional	O
medications	O
,	O
then	O
this	O
will	O
open	O
-	O
up	O
new	O
and	O
potentially	O
empowering	B-OUTCOME
options	I-OUTCOME
for	O
patients	O
and	O
clinicians	O
(	O
as	O
well	O
as	O
a	O
real	O
potential	O
for	O
resistance	O
–	O
however	O
it	O
may	O
arise	O
)	O
.	O
For	O
the	O
brave	O
new	O
psychiatry	O
of	O
the	O
future	O
–	O
that	O
many	O
would	O
like	O
to	O
see	O
(	O
Miller	O
,	O
2010	O
)	O
–	O
decisions	O
about	O
whether	O
to	O
passively	O
endure	O
or	O
actively	O
address	O
,	O
may	O
become	O
increasingly	O
pertinent	O
.	O
-DOCSTART- -X- O O
A	O
main	O
limitation	O
of	O
the	O
present	O
systematic	O
review	O
is	O
the	O
inclusion	O
of	O
a	O
small	O
number	O
of	O
studies	O
(	O
six	O
)	O
with	O
small	O
sample	O
sizes	O
(	O
6–15	O
volunteers	O
)	O
,	O
which	O
limits	O
the	O
generalization	O
of	O
the	O
reported	O
results	O
.	O
Included	O
studies	O
also	O
show	O
a	O
high	O
degree	O
of	O
heterogeneity	O
,	O
and	O
three	O
of	O
the	O
selected	O
citations	O
did	O
not	O
include	O
placebo	O
or	O
a	O
control	O
group	O
(	O
open	O
-	O
label	O
,	O
proof	O
-	O
of	O
-	O
concept	O
studies	O
)	O
.	O
Another	O
important	O
limitation	O
is	O
the	O
difficulty	O
in	O
disentangling	O
placebo	B-OUTCOME
effects	I-OUTCOME
,	O
drug	B-OUTCOME
effects	I-OUTCOME
,	O
and	O
the	O
influence	B-OUTCOME
of	I-OUTCOME
the	I-OUTCOME
psychological	I-OUTCOME
intervention	I-OUTCOME
included	O
in	O
the	O
clinical	O
trial	O
However	O
,	O
despite	O
these	O
important	O
limitations	O
,	O
results	O
consistently	O
showed	O
that	O
ayahuasca	B-DRUG
,	O
psilocybin	B-DRUG
,	O
and	O
LSD	B-DRUG
produced	O
anxiolytic	B-OUTCOME
,	I-OUTCOME
antidepressive	I-OUTCOME
,	I-OUTCOME
and	I-OUTCOME
antiaddictive	I-OUTCOME
effects	I-OUTCOME
in	O
patients	O
,	O
and	O
these	O
results	O
were	O
also	O
observed	O
in	O
animal	O
studies	O
and	O
with	O
healthy	O
volunteers	O
.	O
Given	O
the	O
low	O
success	O
rates	O
of	O
current	B-ANTIDEPRESSANT DRUG
pharmacological	I-ANTIDEPRESSANT DRUG
and	I-ANTIDEPRESSANT DRUG
nonpharmacological	I-ANTIDEPRESSANT DRUG
treatments	I-ANTIDEPRESSANT DRUG
for	O
drug	B-HEALTH CONDITION
dependence	I-HEALTH CONDITION
and	O
anxiety	B-HEALTH CONDITION
and	O
mood	B-HEALTH CONDITION
disorders	I-HEALTH CONDITION
,	O
and	O
considering	O
the	O
high	O
morbidity	O
and	O
mortality	O
associated	O
with	O
these	O
disorders	O
,	O
it	O
is	O
necessary	O
to	O
perform	O
more	O
studies	O
with	O
these	O
drugs	O
,	O
even	O
if	O
only	O
a	O
small	O
portion	O
of	O
patients	O
may	O
reduce	B-OUTCOME
patients	I-OUTCOME
suffering	I-OUTCOME
with	O
these	O
drugs	B-DRUG
.	O
Future	O
studies	O
should	O
include	O
more	O
patients	O
,	O
placebo	O
or	O
active	O
placebo	O
,	O
randomized	O
and	O
double	O
-	O
blind	O
designs	O
,	O
and	O
multiple	O
doses	O
during	O
treatment	O
.	O
Moreover	O
,	O
the	O
influence	O
of	O
psychological	B-OUTCOME
interventions	I-OUTCOME
and	O
the	O
possible	O
increases	O
in	O
therapeutic	B-OUTCOME
efficacy	I-OUTCOME
proportionated	O
by	O
these	O
psychotherapeutic	O
approaches	O
should	O
be	O
better	O
explored	O
Currently	B-ANTIDEPRESSANT DRUG
available	I-ANTIDEPRESSANT DRUG
pharmacological	I-ANTIDEPRESSANT DRUG
treatments	I-ANTIDEPRESSANT DRUG
for	O
drug	B-HEALTH CONDITION
dependence	I-HEALTH CONDITION
and	O
anxiety	B-HEALTH CONDITION
and	O
mood	B-HEALTH CONDITION
disorders	I-HEALTH CONDITION
have	O
limited	B-OUTCOME
efficacy	I-OUTCOME
and	O
often	O
produce	O
important	O
adverse	B-OUTCOME
reactions	I-OUTCOME
that	O
may	O
limit	O
treatment	O
continuation	O
.	O
Classic	O
tryptamine	B-DRUG
hallucinogens	I-DRUG
such	O
as	O
ayahuasca	B-DRUG
/	O
DMT	B-DRUG
,	O
psilocybin	B-DRUG
,	O
and	O
LSD	B-DRUG
are	O
safely	O
administered	O
in	O
controlled	O
settings	O
and	O
several	O
basic	O
,	O
experimental	O
,	O
and	O
clinical	O
studies	O
suggest	O
that	O
these	O
drugs	O
have	O
anxiolytic	B-OUTCOME
,	I-OUTCOME
antidepressive	I-OUTCOME
,	I-OUTCOME
and	I-OUTCOME
antiaddictive	I-OUTCOME
effects	I-OUTCOME
.	O
Such	O
beneficial	B-OUTCOME
properties	I-OUTCOME
seem	O
to	O
be	O
mediated	O
by	O
an	O
agonist	B-NEURAL MECHANISM/CORRELATE
action	I-NEURAL MECHANISM/CORRELATE
of	O
these	O
compounds	O
on	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT1A/2A/2C	I-NEURAL MECHANISM/CORRELATE
receptors	I-NEURAL MECHANISM/CORRELATE
,	O
which	O
are	O
involved	O
in	O
emotional	B-OUTCOME
processing	I-OUTCOME
,	O
regulation	B-OUTCOME
of	I-OUTCOME
neurotrophic	I-OUTCOME
factors	I-OUTCOME
,	O
anti	B-OUTCOME
-	I-OUTCOME
inflammatory	I-OUTCOME
actions	I-OUTCOME
,	O
and	O
modulation	O
of	O
frontal	O
and	O
medial	B-NEURAL MECHANISM/CORRELATE
brain	I-NEURAL MECHANISM/CORRELATE
structures	I-NEURAL MECHANISM/CORRELATE
.	O
Other	O
mechanisms	O
of	O
action	O
not	O
related	O
to	O
serotonergic	B-NEURAL MECHANISM/CORRELATE
receptors	I-NEURAL MECHANISM/CORRELATE
,	O
such	O
as	O
regulation	B-NEURAL MECHANISM/CORRELATE
of	I-NEURAL MECHANISM/CORRELATE
cell	I-NEURAL MECHANISM/CORRELATE
energy	I-NEURAL MECHANISM/CORRELATE
homeostasis	I-NEURAL MECHANISM/CORRELATE
,	O
mitochondrial	B-NEURAL MECHANISM/CORRELATE
functions	I-NEURAL MECHANISM/CORRELATE
,	O
and	O
oxidative	B-NEURAL MECHANISM/CORRELATE
stress	I-NEURAL MECHANISM/CORRELATE
,	O
also	O
appear	O
to	O
mediate	O
these	O
therapeutic	B-OUTCOME
effects	I-OUTCOME
The	O
reviewed	O
studies	O
suggest	O
that	O
the	O
therapeutic	O
use	O
of	O
classic	B-DRUG
hallucinogens	I-DRUG
may	O
offer	O
to	O
some	O
patients	O
fast	B-OUTCOME
-	I-OUTCOME
acting	I-OUTCOME
and	I-OUTCOME
prolonged	I-OUTCOME
beneficial	I-OUTCOME
effects	I-OUTCOME
after	O
a	O
single	O
dose	O
,	O
producing	O
few	O
adverse	B-OUTCOME
effects	I-OUTCOME
.	O
Indeed	O
,	O
interest	O
in	O
the	O
medicinal	O
uses	O
of	O
this	O
class	O
of	O
drugs	O
is	O
increasing	O
:	O
new	O
clinical	O
trials	O
investigating	O
the	O
effects	O
of	O
psilocybin	B-DRUG
in	O
the	O
treatment	O
of	O
alcoholism	B-HEALTH CONDITION
,	O
cocaine	B-HEALTH CONDITION
dependence	I-HEALTH CONDITION
,	O
tobacco	B-HEALTH CONDITION
dependence	I-HEALTH CONDITION
,	O
and	O
anxiety	B-HEALTH CONDITION
and	O
depression	B-HEALTH CONDITION
associated	I-HEALTH CONDITION
with	I-HEALTH CONDITION
cancer	I-HEALTH CONDITION
are	O
currently	O
underway	O
[	O
ClinicalTrials.gov	O
identifiers	O
:	O
NCT02061293	O
,	O
NCT02037126	O
,	O
NCT01943994	O
,	O
NCT00957359	O
,	O
NCT00465595	O
]	O
.	O
Moreover	O
,	O
our	O
group	O
recently	O
replicated	O
the	O
results	O
of	O
the	O
original	O
open	O
-	O
label	O
,	O
proof	O
-	O
of	O
-	O
concept	O
study	O
[	O
Osório	O
et	O
al	O
.	O
2015	O
]	O
but	O
including	O
an	O
increased	O
sample	O
size	O
(	O
n	O
=	O
17	O
)	O
and	O
single	O
-	O
photon	O
emission	O
computed	O
tomography	O
(	O
SPECT	O
)	O
,	O
showing	O
that	O
ayahuasca	B-DRUG
antidepressive	B-OUTCOME
properties	I-OUTCOME
may	O
be	O
associated	O
with	O
increased	B-OUTCOME
blood	I-OUTCOME
perfusion	I-OUTCOME
in	O
brain	B-NEURAL MECHANISM/CORRELATE
areas	O
related	O
to	O
depressive	B-HEALTH CONDITION
symptoms	I-HEALTH CONDITION
(	O
Sanches	O
et	O
al	O
.	O
2016	O
“	O
This	O
reference	O
was	O
not	O
included	O
in	O
the	O
review	O
because	O
This	O
reference	O
was	O
not	O
published	O
at	O
the	O
time	O
of	O
the	O
electronic	O
search	O
”	O
)	O
.	O
Our	O
group	O
is	O
currently	O
performing	O
randomized	O
,	O
double	O
blind	O
,	O
placebo	O
-	O
controlled	O
studies	O
assessing	O
the	O
antidepressive	B-OUTCOME
and	I-OUTCOME
anxiolytic	I-OUTCOME
potentials	I-OUTCOME
of	O
ayahuasca	B-DRUG
[	O
Frood	O
,	O
2015	O
]	O
Further	O
studies	O
are	O
urgently	O
needed	O
to	O
better	O
understand	O
the	O
effects	O
of	O
classical	O
tryptamine	B-DRUG
hallucinogens	I-DRUG
in	O
psychiatric	B-HEALTH CONDITION
disorders	I-HEALTH CONDITION
.	O
-DOCSTART- -X- O O
The	O
results	O
of	O
this	O
study	O
are	O
consistent	O
with	O
our	O
previous	O
population	O
study	O
,	O
early	O
and	O
recent	O
randomized	O
controlled	O
trials	O
,	O
studies	O
of	O
regular	O
participants	O
in	O
legally	O
recognized	O
psychedelic	O
religious	O
ceremonies	O
,	O
drug	B-DRUG
education	O
materials	O
from	O
public	O
agencies	O
and	O
recent	O
expert	O
assessments	O
of	O
drug	B-OUTCOME
harms	I-OUTCOME
(	O
Krebs	O
and	O
Johansen	O
,	O
2013b	O
)	O
.	O
There	O
is	O
little	O
evidence	O
linking	O
psychedelic	B-DRUG
use	O
to	O
lasting	B-OUTCOME
mental	I-OUTCOME
health	I-OUTCOME
problems	I-OUTCOME
.	O
In	O
general	O
,	O
use	O
of	O
psychedelics	B-DRUG
does	O
not	O
appear	O
to	O
be	O
particularly	O
dangerous	O
when	O
compared	O
to	O
other	O
activities	O
considered	O
to	O
have	O
acceptable	O
safety	O
.	O
It	O
is	O
important	O
to	O
take	O
a	O
statistical	O
perspective	O
to	O
risk	O
,	O
rather	O
than	O
focusing	O
on	O
case	O
reports	O
and	O
anecdotes	O
:	O
‘	O
Nothing	O
in	O
life	O
is	O
free	O
from	O
risk	O
–	O
risk	O
is	O
simply	O
impossible	O
to	O
avoid	O
…	O
Even	O
ordinary	O
activities	O
–	O
eating	O
breakfast	O
,	O
watching	O
television	O
,	O
walking	O
the	O
dog	O
–	O
carry	O
risks	O
,	O
however	O
minor	O
’	O
(	O
BMA	O
,	O
2012	O
)	O
.	O
As	O
Steven	O
Pinker	O
recently	O
noted	O
,	O
‘	O
In	O
a	O
free	O
society	O
,	O
one	O
can	O
not	O
empower	O
the	O
government	O
to	O
outlaw	O
any	O
behavior	B-OUTCOME
that	O
offends	O
someone	O
just	O
because	O
the	O
offendee	O
can	O
pull	O
a	O
hypothetical	O
future	O
injury	O
out	O
of	O
the	O
air	O
’	O
(	O
Pinker	O
,	O
2008	O
)	O
.	O
Overall	O
,	O
it	O
is	O
difficult	O
to	O
see	O
how	O
prohibition	B-OUTCOME
of	I-OUTCOME
psychedelics	I-OUTCOME
can	O
be	O
justified	O
from	O
a	O
public	B-HEALTH CONDITION
health	I-HEALTH CONDITION
or	O
human	O
rights	O
perspective	O
.	O
-DOCSTART- -X- O O
Ayahuasca	B-DRUG
has	O
a	O
long	O
history	O
of	O
ceremonial	O
use	O
and	O
Ayahuasca	B-DRUG
recent	O
worldwide	O
expansion	O
is	O
providing	O
an	O
unprecedented	O
opportunity	O
to	O
study	O
Ayahuasca	B-DRUG
impact	O
on	O
human	O
health	O
.	O
An	O
increasing	O
number	O
of	O
papers	O
suggest	O
reasonable	B-OUTCOME
safety	I-OUTCOME
and	O
benefits	O
in	O
mood	B-OUTCOME
and	O
psychiatry	B-OUTCOME
symptoms	I-OUTCOME
in	O
the	O
areas	O
of	O
substance	B-HEALTH CONDITION
use	I-HEALTH CONDITION
disorders	I-HEALTH CONDITION
,	O
anxiety	B-HEALTH CONDITION
and	O
depression	B-HEALTH CONDITION
Preliminary	O
findings	O
on	O
the	O
potential	O
psychological	O
mechanisms	O
associated	O
with	O
therapeutic	B-OUTCOME
benefits	I-OUTCOME
indicate	O
similarities	O
with	O
mindfulness	O
-	O
based	O
therapy	O
.	O
Ayahuasca	B-DRUG
appears	O
to	O
enhance	O
self	B-OUTCOME
-	I-OUTCOME
acceptance	I-OUTCOME
and	I-OUTCOME
decentering	I-OUTCOME
,	O
crucial	O
aspects	O
associated	O
with	O
psychotherapeutic	O
treatment	O
outcome	O
in	O
several	O
psychiatric	B-HEALTH CONDITION
disorders	I-HEALTH CONDITION
.	O
From	O
a	O
neural	O
perspective	O
,	O
neuroimaging	O
studies	O
after	O
an	O
ayahuasca	B-DRUG
intake	O
have	O
reported	O
activation	O
in	O
areas	O
associated	O
with	O
emotional	B-OUTCOME
processing	I-OUTCOME
and	O
memory	B-OUTCOME
formation	I-OUTCOME
.	O
These	O
results	O
suggest	O
that	O
similarly	O
to	O
exposure	O
therapies	O
,	O
ayahuasca	B-DRUG
allows	O
reviewing	B-OUTCOME
emotional	I-OUTCOME
events	I-OUTCOME
,	O
but	O
with	O
increased	B-OUTCOME
vividness	I-OUTCOME
and	I-OUTCOME
sense	I-OUTCOME
of	I-OUTCOME
“	I-OUTCOME
reality	I-OUTCOME
”	I-OUTCOME
.	O
We	O
postulate	O
that	O
the	O
state	B-SUBJECTIVE EXPERIENCE
induced	O
by	O
ayahuasca	B-DRUG
could	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
trauma	B-HEALTH CONDITION
,	O
substance	B-HEALTH CONDITION
use	I-HEALTH CONDITION
disorders	I-HEALTH CONDITION
,	O
impulsive	B-HEALTH CONDITION
-	I-HEALTH CONDITION
related	I-HEALTH CONDITION
disorders	I-HEALTH CONDITION
,	O
and	O
certain	O
patients	O
suffering	O
from	O
borderline	B-HEALTH CONDITION
personality	I-HEALTH CONDITION
disorder	I-HEALTH CONDITION
More	O
research	O
is	O
warranted	O
in	O
clinical	O
populations	O
,	O
using	O
larger	O
samples	O
,	O
matched	O
comparison	O
groups	O
,	O
randomized	O
designs	O
and	O
blinded	O
raters	O
to	O
confirm	O
More	O
research	O
efficacy	O
.	O
Finally	O
,	O
it	O
will	O
be	O
necessary	O
for	O
future	O
studies	O
to	O
implement	O
adequate	O
settings	O
and	O
involve	O
clinicians	O
with	O
specific	O
training	O
to	O
ensure	O
the	O
safety	O
of	O
participants	O
.	O
-DOCSTART- -X- O O
The	O
current	O
report	O
provides	O
preliminary	O
evidence	O
that	O
psilocybin	B-DRUG
administration	O
may	O
lead	O
to	O
shifts	B-OUTCOME
in	I-OUTCOME
affect	I-OUTCOME
and	I-OUTCOME
the	I-OUTCOME
neural	I-OUTCOME
correlates	I-OUTCOME
of	I-OUTCOME
affective	I-OUTCOME
processing	I-OUTCOME
that	O
endure	O
beyond	O
acute	O
drug	B-OUTCOME
effects	I-OUTCOME
.	O
Within	O
a	O
dimensional	O
or	O
domain	O
-	O
based	O
taxonomy	O
of	O
brain	B-NEURAL MECHANISM/CORRELATE
function	I-NEURAL MECHANISM/CORRELATE
and	O
pathology	O
,	O
the	O
reported	O
findings	O
are	O
consistent	O
with	O
a	O
trans	O
-	O
diagnostic	O
process	O
that	O
may	O
underlie	O
both	O
mood	B-HEALTH CONDITION
and	I-HEALTH CONDITION
substance	I-HEALTH CONDITION
use	I-HEALTH CONDITION
disorders	I-HEALTH CONDITION
.	O
Reduction	B-OUTCOME
of	I-OUTCOME
negative	I-OUTCOME
affect	I-OUTCOME
may	O
undermine	O
ruminative	B-OUTCOME
processes	I-OUTCOME
that	O
contribute	O
to	O
the	O
development	O
and	O
maintenance	O
of	O
mood	B-HEALTH CONDITION
disorders	I-HEALTH CONDITION
,	O
and	O
these	O
effects	O
are	O
consistent	O
with	O
psychological	B-OUTCOME
and	I-OUTCOME
neural	I-OUTCOME
changes	I-OUTCOME
that	O
might	O
be	O
expected	O
to	O
accompany	O
antidepressant	B-OUTCOME
effects	I-OUTCOME
of	O
psilocybin	B-DRUG
.	O
Disruption	B-OUTCOME
of	I-OUTCOME
the	I-OUTCOME
negative	I-OUTCOME
components	I-OUTCOME
of	I-OUTCOME
craving	I-OUTCOME
and	I-OUTCOME
withdrawal	I-OUTCOME
may	O
undermine	O
the	O
development	O
and	O
maintenance	O
of	O
substance	B-HEALTH CONDITION
use	I-HEALTH CONDITION
disorders	I-HEALTH CONDITION
,	O
consistent	O
with	O
psychological	O
and	O
clinical	O
changes	O
observed	O
in	O
patients	O
with	O
tobacco	O
and	O
alcohol	B-HEALTH CONDITION
use	I-HEALTH CONDITION
disorders	I-HEALTH CONDITION
.	O
Reported	O
findings	O
may	O
also	O
account	O
for	O
long	B-OUTCOME
-	I-OUTCOME
term	I-OUTCOME
positive	I-OUTCOME
changes	I-OUTCOME
in	I-OUTCOME
mood	I-OUTCOME
,	I-OUTCOME
attitude	I-OUTCOME
,	I-OUTCOME
and	I-OUTCOME
well	I-OUTCOME
-	I-OUTCOME
being	I-OUTCOME
that	O
have	O
been	O
reported	O
in	O
healthy	O
individuals	O
While	O
both	O
negative	B-OUTCOME
affect	I-OUTCOME
and	O
brain	B-OUTCOME
response	I-OUTCOME
to	O
affective	O
stimuli	O
were	O
reduced	O
1	O
week	O
after	O
psilocybin	B-DRUG
,	O
both	O
rebounded	O
at	O
the	O
1	O
month	O
timepoint	O
,	O
suggesting	O
that	O
psilocybin	B-DRUG
may	O
have	O
initiated	O
a	O
dynamic	B-OUTCOME
and	I-OUTCOME
neuroplastic	I-OUTCOME
process	I-OUTCOME
that	O
was	O
sustained	O
for	O
at	O
least	O
a	O
number	O
of	O
weeks	O
.	O
It	O
is	O
possible	O
that	O
such	O
a	O
neuroplastic	B-OUTCOME
period	I-OUTCOME
may	O
allow	O
for	O
a	O
more	O
enduring	B-OUTCOME
shift	I-OUTCOME
towards	I-OUTCOME
positive	I-OUTCOME
affective	I-OUTCOME
.	O
The	O
observed	O
increase	O
in	O
functional	B-NEURAL MECHANISM/CORRELATE
connectivity	I-NEURAL MECHANISM/CORRELATE
strength	O
indiscriminately	O
across	O
networks	O
may	O
reflect	O
a	O
domain	B-OUTCOME
-	I-OUTCOME
general	I-OUTCOME
cortical	I-OUTCOME
plasticity	I-OUTCOME
process	I-OUTCOME
supporting	O
the	O
observed	O
changes	O
in	O
affective	B-OUTCOME
processing	I-OUTCOME
,	O
consistent	O
with	O
preclinical	O
evidence	O
for	O
psychoplastogenic	O
properties	O
of	O
psychedelic	B-DRUG
drugs45,90	O
.	O
Overall	O
,	O
the	O
current	O
findings	O
identify	O
negative	B-OUTCOME
affect	I-OUTCOME
as	O
a	O
potential	O
therapeutic	O
target	O
of	O
psilocybin	B-DRUG
-DOCSTART- -X- O O
In	O
the	O
search	O
of	O
neuronal	B-NEURAL MECHANISM/CORRELATE
correlates	I-NEURAL MECHANISM/CORRELATE
of	O
altered	B-SUBJECTIVE EXPERIENCE
states	I-SUBJECTIVE EXPERIENCE
of	I-SUBJECTIVE EXPERIENCE
consciousness	I-SUBJECTIVE EXPERIENCE
induced	O
by	O
LSD	B-DRUG
,	O
we	O
could	O
replicate	O
previous	O
findings	O
describing	O
decreased	B-OUTCOME
functional	I-OUTCOME
connectivity	I-OUTCOME
within	O
RSNs	B-NEURAL MECHANISM/CORRELATE
.	O
However	O
,	O
the	O
relevance	O
and	O
specificity	O
of	O
these	O
alterations	O
for	O
LSD	B-OUTCOME
-	I-OUTCOME
induced	I-OUTCOME
effects	I-OUTCOME
are	O
questioned	O
by	O
lacking	O
associations	O
with	O
subjective	B-OUTCOME
drug	I-OUTCOME
effects	I-OUTCOME
as	O
well	O
as	O
very	O
similar	O
observations	O
obtained	O
after	O
the	O
administration	O
of	O
a	O
serotonin	B-ANTIDEPRESSANT DRUG
reuptake	I-ANTIDEPRESSANT DRUG
inhibitor	I-ANTIDEPRESSANT DRUG
.	O
In	O
line	O
with	O
previous	O
results	O
,	O
we	O
found	O
widely	O
increased	B-OUTCOME
between	I-OUTCOME
-	I-OUTCOME
network	I-OUTCOME
connectivity	I-OUTCOME
.	O
Closer	O
inspection	O
,	O
however	O
,	O
indicated	O
very	O
little	O
consistencies	O
in	O
altered	B-NEURAL MECHANISM/CORRELATE
FC	I-NEURAL MECHANISM/CORRELATE
between	O
specific	O
RSNs	B-NEURAL MECHANISM/CORRELATE
in	O
our	O
sample	O
and	O
previous	O
findings	O
in	O
LSD	B-DRUG
and	O
psilocybin	B-DRUG
.	O
Therefore	O
,	O
it	O
seems	O
doubtful	O
that	O
one	O
of	O
these	O
measures	O
is	O
a	O
reliable	O
and	O
characteristic	O
neuronal	B-NEURAL MECHANISM/CORRELATE
correlate	I-NEURAL MECHANISM/CORRELATE
of	O
hallucinogenic	B-OUTCOME
drug	I-OUTCOME
effects	I-OUTCOME
.	O
Importantly	O
,	O
our	O
results	O
indicated	O
increased	B-OUTCOME
connectivity	I-OUTCOME
between	I-OUTCOME
networks	I-OUTCOME
and	O
subcortical	B-NEURAL MECHANISM/CORRELATE
and	O
cortical	B-NEURAL MECHANISM/CORRELATE
hub	I-NEURAL MECHANISM/CORRELATE
structures	I-NEURAL MECHANISM/CORRELATE
.	O
This	O
finding	O
is	O
in	O
line	O
with	O
previous	O
observations	O
in	O
psychopathological	O
states	B-SUBJECTIVE EXPERIENCE
,	O
especially	O
in	O
psychosis	B-HEALTH CONDITION
.	O
According	O
to	O
a	O
recent	O
model	O
,	O
altered	B-NEURAL MECHANISM/CORRELATE
hub	I-NEURAL MECHANISM/CORRELATE
connectivity	I-NEURAL MECHANISM/CORRELATE
might	O
also	O
explain	O
improvements	O
observed	O
in	O
various	O
mental	B-HEALTH CONDITION
diseases	I-HEALTH CONDITION
after	O
the	O
administration	O
of	O
hallucinogens	B-DRUG
.	O
-DOCSTART- -X- O O
The	O
present	O
review	O
looked	O
at	O
classical	O
psychedelics	B-DRUG
for	O
the	O
treatment	O
of	O
depression	B-HEALTH CONDITION
and	O
anxiety	B-HEALTH CONDITION
associated	O
with	O
life	B-HEALTH CONDITION
-	I-HEALTH CONDITION
threatening	I-HEALTH CONDITION
disease	I-HEALTH CONDITION
.	O
The	O
present	O
review	O
found	O
that	O
,	O
in	O
a	O
supportive	O
setting	O
,	O
ayahuasca	B-DRUG
,	O
psilocybin	B-DRUG
,	O
and	O
LSD	B-DRUG
consistently	O
produced	O
significant	O
and	O
sustained	O
anti	B-OUTCOME
-	I-OUTCOME
depressant	I-OUTCOME
and	I-OUTCOME
anxiolytic	I-OUTCOME
effects	I-OUTCOME
.	O
Psychedelic	O
treatment	O
was	O
generally	O
well	O
-	O
tolerated	O
with	O
no	B-OUTCOME
persisting	I-OUTCOME
adverse	I-OUTCOME
effects	I-OUTCOME
.	O
Regarding	O
their	O
mechanisms	O
of	O
action	O
,	O
their	O
mediate	O
their	O
main	O
therapeutic	B-OUTCOME
effects	I-OUTCOME
biochemically	O
via	O
serotonin	B-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
agonism	I-NEURAL MECHANISM/CORRELATE
,	O
and	O
psychologically	O
by	O
generating	O
meaningful	O
psycho	B-SUBJECTIVE EXPERIENCE
-	I-SUBJECTIVE EXPERIENCE
spiritual	I-SUBJECTIVE EXPERIENCE
experiences	I-SUBJECTIVE EXPERIENCE
that	O
contribute	O
to	O
mental	B-OUTCOME
flexibility	I-OUTCOME
Given	O
the	O
limited	O
success	O
rates	O
of	O
current	O
treatments	O
for	O
anxiety	B-HEALTH CONDITION
and	O
mood	B-HEALTH CONDITION
disorders	I-HEALTH CONDITION
,	O
and	O
considering	O
the	O
high	O
morbidity	O
associated	O
with	O
these	O
conditions	O
,	O
there	O
is	O
potential	O
for	O
psychedelics	B-DRUG
to	O
provide	O
symptom	B-OUTCOME
relief	I-OUTCOME
in	O
patients	O
inadequately	O
managed	O
by	O
conventional	O
methods	O
.	O
The	O
novelty	O
of	O
this	O
research	O
means	O
that	O
before	O
psychedelics	B-DRUG
’	O
wider	O
-	O
use	O
can	O
be	O
contemplated	O
,	O
the	O
results	O
presented	O
herein	O
need	O
to	O
be	O
replicated	O
in	O
larger	O
studies	O
with	O
a	O
longer	O
follow	O
-	O
up	O
to	O
determine	O
lasting	B-OUTCOME
efficacy	I-OUTCOME
and	I-OUTCOME
safety	I-OUTCOME
.	O
Moreover	O
,	O
the	O
role	O
of	O
psychotherapy	B-OUTCOME
as	O
an	O
adjunct	O
to	O
psychedelic	B-DRUG
treatment	O
should	O
be	O
better	O
explored	O
.	O
Ultimately	O
,	O
this	O
would	O
help	O
to	O
improve	O
the	O
care	O
of	O
patients	O
suffering	O
from	O
depression	B-HEALTH CONDITION
and	O
anxiety	B-HEALTH CONDITION
.	O
-DOCSTART- -X- O O
In	O
summary	O
,	O
the	O
findings	O
of	O
this	O
LTFU	O
study	O
represent	O
the	O
first	O
suggestion	O
of	O
persistent	B-OUTCOME
long	I-OUTCOME
-	I-OUTCOME
term	I-OUTCOME
effects	I-OUTCOME
of	O
psilocybin	B-DRUG
-	O
assisted	O
psychotherapy	O
for	O
cancer	B-HEALTH CONDITION
-	I-HEALTH CONDITION
related	I-HEALTH CONDITION
distress	I-HEALTH CONDITION
.	O
Although	O
limited	O
conclusions	O
can	O
be	O
drawn	O
regarding	O
efficacy	B-OUTCOME
due	O
to	O
the	O
crossover	O
design	O
,	O
results	O
suggests	O
that	O
the	O
treatment	O
continues	O
to	O
be	O
associated	O
with	O
reductions	O
in	O
anxiety	B-HEALTH CONDITION
,	O
depression	B-HEALTH CONDITION
,	O
hopelessness	B-SUBJECTIVE EXPERIENCE
,	O
demoralization	B-SUBJECTIVE EXPERIENCE
,	O
and	O
death	B-HEALTH CONDITION
anxiety	I-HEALTH CONDITION
up	O
to	O
an	O
average	O
of	O
4.5	O
years	O
following	O
a	O
single	O
psilocybin	B-DRUG
session	O
in	O
conjunction	O
with	O
psychotherapy	O
.	O
Theories	O
regarding	O
neurobiological	B-NEURAL MECHANISM/CORRELATE
and	O
psychological	B-NEURAL MECHANISM/CORRELATE
change	I-NEURAL MECHANISM/CORRELATE
mechanisms	I-NEURAL MECHANISM/CORRELATE
remain	O
speculative	O
and	O
exploratory	O
.	O
Further	O
research	O
will	O
need	O
to	O
validate	O
the	O
main	O
findings	O
of	O
the	O
parent	O
trial	O
and	O
this	O
LTFU	O
article	O
with	O
a	O
fully	O
experimental	O
design	O
in	O
order	O
to	O
empirically	O
establish	O
the	O
use	O
of	O
psilocybin	B-DRUG
-	O
assisted	O
psychotherapy	O
to	O
treat	O
the	O
psychiatric	O
and	O
existential	B-HEALTH CONDITION
distress	I-HEALTH CONDITION
of	O
those	O
with	O
life	B-HEALTH CONDITION
-	I-HEALTH CONDITION
threatening	I-HEALTH CONDITION
cancer	I-HEALTH CONDITION
diagnoses	O
An	O
advanced	O
experimental	O
design	O
of	O
psilocybin	B-DRUG
-	O
assisted	O
psychotherapy	O
would	O
likely	O
include	O
a	O
larger	O
sample	O
size	O
(	O
i.e.	O
N=200	O
)	O
that	O
is	O
nationally	O
representative	O
of	O
cancer	B-HEALTH CONDITION
patients	O
.	O
An	O
advanced	O
experimental	O
design	O
of	O
psilocybin	B-DRUG
-	O
assisted	O
psychotherapy	O
would	O
also	O
include	O
randomized	O
,	O
parallel	O
groups	O
without	O
a	O
crossover	O
,	O
use	O
of	O
an	O
adequate	O
placebo	O
control	O
group	O
,	O
measures	O
taken	O
to	O
minimize	O
blinding	O
and	O
expectancy	O
effects	O
,	O
and	O
the	O
use	O
of	O
valid	O
and	O
reliable	O
outcome	B-OUTCOME
measures	I-OUTCOME
.	O
An	O
advanced	O
experimental	O
design	O
of	O
psilocybin	B-DRUG
-	O
assisted	O
psychotherapy	O
might	O
also	O
include	O
design	O
elements	O
that	O
would	O
allow	O
for	O
exploration	O
of	O
potential	O
neurobiological	B-NEURAL MECHANISM/CORRELATE
(	O
e.g.	O
growth	B-NEURAL MECHANISM/CORRELATE
factor	I-NEURAL MECHANISM/CORRELATE
expression	I-NEURAL MECHANISM/CORRELATE
,	O
functional	B-NEURAL MECHANISM/CORRELATE
connectivity	I-NEURAL MECHANISM/CORRELATE
,	O
neuroplasticity	B-NEURAL MECHANISM/CORRELATE
)	O
and	O
psychological	O
(	O
e.g.	O
mystical	B-SUBJECTIVE EXPERIENCE
experience	I-SUBJECTIVE EXPERIENCE
,	O
personality	O
,	O
psychological	B-OUTCOME
flexibility	I-OUTCOME
,	O
emotional	B-OUTCOME
breakthroughs	I-OUTCOME
and	O
insights	B-SUBJECTIVE EXPERIENCE
,	O
challenging	B-OUTCOME
experiences	I-OUTCOME
)	O
mechanisms	O
of	O
action	O
of	O
psilocybin	B-DRUG
-	O
assisted	O
therapy	O
Funding	O
for	O
psychedelic	O
research	O
in	O
the	O
USA	O
remains	O
mostly	O
limited	O
to	O
the	O
private	O
sector	O
at	O
present	O
time	O
.	O
It	O
would	O
be	O
an	O
historic	O
and	O
important	O
milestone	O
if	O
the	O
National	O
Institutes	O
of	O
Health	O
were	O
to	O
fund	O
advanced	O
research	O
exploring	O
the	O
therapeutic	B-OUTCOME
potential	I-OUTCOME
of	O
psilocybin	B-DRUG
-	O
assisted	O
psychotherapy	O
in	O
patients	O
with	O
life	B-HEALTH CONDITION
-	I-HEALTH CONDITION
threatening	I-HEALTH CONDITION
cancer	I-HEALTH CONDITION
and	O
concomitant	O
psychiatric	O
and	O
existential	B-HEALTH CONDITION
distress	I-HEALTH CONDITION
.	O
If	O
the	O
Food	O
and	O
Drug	B-DRUG
Administration	O
were	O
to	O
sanction	O
this	O
next	O
phase	O
of	O
research	O
(	O
i.e.	O
phase	O
III	O
trials	O
)	O
for	O
this	O
clinical	O
indication	O
,	O
and	O
favorable	O
findings	O
were	O
to	O
emerge	O
,	O
the	O
Food	O
and	O
Drug	B-DRUG
Administration	O
could	O
help	O
to	O
form	O
a	O
pathway	O
for	O
psilocybin	B-DRUG
to	O
become	O
re	O
-	O
scheduled	O
and	O
clinically	O
available	O
for	O
cancer	B-HEALTH CONDITION
patients	O
.	O
the	O
Food	O
and	O
Drug	B-DRUG
Administration	O
would	O
represent	O
a	O
major	O
paradigm	O
shift	O
in	O
the	O
psycho	O
-	O
oncological	O
approach	O
and	O
care	O
of	O
patients	O
with	O
cancer	B-HEALTH CONDITION
.	O
The	O
use	O
of	O
psilocybin	B-DRUG
-	O
assisted	O
psychotherapy	O
for	O
those	O
with	O
life	B-HEALTH CONDITION
-	I-HEALTH CONDITION
threatening	I-HEALTH CONDITION
cancer	I-HEALTH CONDITION
could	O
be	O
especially	O
useful	O
in	O
helping	O
patients	O
approach	O
those	O
with	O
life	B-HEALTH CONDITION
-	I-HEALTH CONDITION
threatening	I-HEALTH CONDITION
cancer	I-HEALTH CONDITION
lives	O
with	O
enhanced	B-OUTCOME
psychological	I-OUTCOME
,	I-OUTCOME
emotional	I-OUTCOME
,	I-OUTCOME
and	I-OUTCOME
spiritual	I-OUTCOME
wellbeing	I-OUTCOME
-DOCSTART- -X- O O
This	O
study	O
used	O
qualitative	O
methods	O
to	O
describe	O
the	O
subjective	B-OUTCOME
experiences	I-OUTCOME
of	O
those	O
who	O
underwent	O
psilocybin	B-DRUG
treatment	O
for	O
cancer	B-HEALTH CONDITION
-	I-HEALTH CONDITION
related	I-HEALTH CONDITION
emotional	I-HEALTH CONDITION
distress	I-HEALTH CONDITION
.	O
This	O
study	O
identifies	O
major	O
narrative	O
themes	O
that	O
contributed	O
to	O
alleviation	O
of	O
those	O
who	O
underwent	O
psilocybin	B-DRUG
treatment	O
for	O
cancer	B-HEALTH CONDITION
-	I-HEALTH CONDITION
related	I-HEALTH CONDITION
emotional	I-HEALTH CONDITION
distress	I-HEALTH CONDITION
anxiety	B-HEALTH CONDITION
and	O
despair	B-HEALTH CONDITION
,	O
complementing	O
two	O
quantitative	O
studies	O
in	O
the	O
same	O
area	O
(	O
Griffiths	O
et	O
al	O
.	O
,	O
2016	O
;	O
Ross	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
Our	O
study	O
provides	O
support	O
for	O
the	O
psilocybin	B-DRUG
-	O
assisted	O
psychotherapy	O
treatment	O
approach	O
,	O
which	O
is	O
unique	O
in	O
This	O
study	O
capacity	O
to	O
induce	O
rapid	B-OUTCOME
,	I-OUTCOME
substantial	I-OUTCOME
,	I-OUTCOME
and	I-OUTCOME
enduring	I-OUTCOME
benefits	I-OUTCOME
in	O
anxiety	B-HEALTH CONDITION
and	O
depression	B-HEALTH CONDITION
and	O
to	O
occasion	B-OUTCOME
deeply	I-OUTCOME
meaningful	I-OUTCOME
experiences	I-OUTCOME
and	O
new	B-OUTCOME
perspectives	I-OUTCOME
for	O
individuals	O
struggling	O
to	O
assimilate	O
the	O
existential	O
reality	O
of	O
cancer	B-HEALTH CONDITION
into	O
their	O
lives	O
.	O
For	O
the	O
cancer	B-HEALTH CONDITION
patient	O
,	O
especially	O
those	O
seeking	O
relief	O
through	O
greater	O
meaning	O
and	O
understanding	O
of	O
the	O
emotional	O
and	O
existential	O
implications	O
of	O
a	O
life	O
-	O
threatening	O
illness	O
,	O
a	O
therapeutically	O
supported	O
psilocybin	B-DRUG
experience	O
may	O
serve	O
as	O
a	O
powerful	B-OUTCOME
intervention	I-OUTCOME
.	O
We	O
conclude	O
that	O
the	O
psilocybin	B-DRUG
-	O
assisted	O
psychotherapy	O
paradigm	O
has	O
the	O
potential	O
to	O
complement	O
the	O
delivery	B-OUTCOME
of	I-OUTCOME
medical	I-OUTCOME
care	I-OUTCOME
and	O
psychological	O
treatment	O
for	O
individuals	O
with	O
cancer	B-HEALTH CONDITION
whose	O
diagnosis	O
precipitates	O
debilitating	O
psychological	B-HEALTH CONDITION
and	I-HEALTH CONDITION
existential	I-HEALTH CONDITION
distress	I-HEALTH CONDITION
.	O
-DOCSTART- -X- O O
We	O
characterized	O
the	O
effects	O
of	O
LSD	B-DRUG
at	O
different	O
doses	O
to	O
support	O
the	O
dosing	O
of	O
LSD	B-DRUG
for	O
research	O
and	O
LSD	B-DRUG
-	O
assisted	O
therapy	O
.	O
LSD	B-DRUG
exhibited	O
dose	O
-	O
proportional	O
PKs	O
and	O
first	O
-	O
order	O
elimination	O
.	O
LSD	B-DRUG
produced	O
significant	O
dose	O
-	O
dependent	O
subjective	B-OUTCOME
responses	I-OUTCOME
starting	O
at	O
the	O
25	O
µg	O
dose	O
.	O
A	O
ceiling	O
effect	O
was	O
observed	O
for	O
good	B-OUTCOME
drug	I-OUTCOME
effects	I-OUTCOME
at	O
the	O
100	O
µg	O
dose	O
.	O
The	O
200	O
µg	O
dose	O
induced	O
more	O
ego	B-SUBJECTIVE EXPERIENCE
dissolution	I-SUBJECTIVE EXPERIENCE
but	O
also	O
more	O
anxiety	B-HEALTH CONDITION
than	O
the	O
100	O
µg	O
dose	O
.	O
These	O
results	O
may	O
assist	O
with	O
dose	O
finding	O
for	O
future	O
LSD	B-DRUG
research	O
.	O
Ketanserin	B-DRUG
almost	O
completely	O
prevented	O
the	O
response	O
to	O
the	O
high	O
(	O
200	O
µg	O
)	O
dose	O
of	O
LSD	B-DRUG
,	O
thus	O
confirming	O
the	O
critical	O
role	O
of	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptors	I-NEURAL MECHANISM/CORRELATE
in	O
mediating	O
psychedelic	B-OUTCOME
effects	I-OUTCOME
of	O
LSD	B-DRUG
.	O
-DOCSTART- -X- O O
The	O
antidepressant	B-OUTCOME
-	I-OUTCOME
like	I-OUTCOME
and	I-OUTCOME
anxiolytic	I-OUTCOME
effects	I-OUTCOME
of	O
psychedelics	B-DRUG
are	O
measurable	O
and	O
significant	O
in	O
males	O
of	O
a	O
rat	O
experimental	O
system	O
that	O
has	O
been	O
used	O
by	O
several	O
other	O
groups	O
over	O
many	O
decades	O
for	O
the	O
study	O
of	O
mood	B-HEALTH CONDITION
disorders	I-HEALTH CONDITION
in	O
humans	O
.	O
These	O
effects	O
are	O
evident	O
many	O
weeks	O
after	O
administration	O
,	O
are	O
more	O
persistent	O
than	O
those	O
of	O
ketamine	B-DRUG
,	O
and	O
are	O
modulated	O
by	O
the	O
rats	O
’	O
experiences	O
in	O
the	O
first	O
week	O
following	O
administration	O
.	O
The	O
more	O
persistent	B-OUTCOME
therapeutic	I-OUTCOME
effects	I-OUTCOME
of	O
a	O
single	O
administration	O
of	O
psilocybin	B-DRUG
compared	O
to	O
ketamine	B-DRUG
in	O
our	O
experimental	O
system	O
support	O
the	O
notion	O
that	O
serotonin	B-NEURAL MECHANISM/CORRELATE
5	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
directed	O
therapeutic	O
strategies	O
may	O
be	O
superior	O
to	O
ketamine	B-DRUG
-	O
based	O
treatments	O
in	O
the	O
clinic	O
for	O
depression	B-HEALTH CONDITION
.	O
Finally	O
,	O
our	O
experimental	O
rodent	O
system	O
,	O
which	O
recapitulates	O
the	O
major	O
features	O
of	O
psilocybin	B-DRUG
to	O
treat	O
depression	B-HEALTH CONDITION
in	O
human	O
patients	O
,	O
may	O
represent	O
a	O
valuable	O
system	O
to	O
utilize	O
for	O
the	O
elucidation	O
of	O
molecular	B-NEURAL MECHANISM/CORRELATE
,	O
cellular	B-NEURAL MECHANISM/CORRELATE
,	O
and	O
genetic	B-NEURAL MECHANISM/CORRELATE
mechanisms	I-NEURAL MECHANISM/CORRELATE
underlying	O
the	O
ability	O
of	O
psilocybin	B-DRUG
to	O
produce	O
the	O
robust	B-OUTCOME
and	I-OUTCOME
long	I-OUTCOME
lasting	I-OUTCOME
antidepressant	I-OUTCOME
effects	I-OUTCOME
found	O
in	O
human	O
clinical	O
trials	O
toward	O
developing	O
new	O
and	O
effective	O
therapeutic	O
strategies	O
for	O
treating	O
depression	B-HEALTH CONDITION
.	O
-DOCSTART- -X- O O
In	O
summary	O
,	O
the	O
current	O
results	O
close	O
major	O
knowledge	O
-	O
gaps	O
regarding	O
the	O
neurobiology	B-NEURAL MECHANISM/CORRELATE
and	O
neuropharmacology	O
of	O
LSD	B-DRUG
.	O
First	O
,	O
we	O
show	O
that	O
LSD	B-DRUG
induces	O
widespread	O
alterations	B-OUTCOME
of	I-OUTCOME
GBC	I-OUTCOME
in	I-OUTCOME
cortical	I-OUTCOME
and	I-OUTCOME
subcortical	I-OUTCOME
brain	I-OUTCOME
areas	O
,	O
characterized	O
by	O
a	O
synchronization	B-OUTCOME
of	I-OUTCOME
sensory	I-OUTCOME
and	I-OUTCOME
somatomotor	I-OUTCOME
functional	I-OUTCOME
networks	I-OUTCOME
and	O
dis	B-OUTCOME
-	I-OUTCOME
integration	I-OUTCOME
of	I-OUTCOME
associative	I-OUTCOME
networks	I-OUTCOME
.	O
we	O
show	O
that	O
this	O
effect	O
is	O
sensitive	O
to	O
GSR	B-NEURAL MECHANISM/CORRELATE
,	O
which	O
has	O
important	O
implications	O
for	O
future	O
pharmacological	O
resting	O
-	O
state	O
studies	O
.	O
Second	O
,	O
we	O
investigated	O
the	O
receptor	O
-	O
pharmacology	O
of	O
LSD	B-DRUG
,	O
showing	O
that	O
the	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptor	O
plays	O
a	O
critical	O
role	O
in	O
subjective	B-OUTCOME
and	I-OUTCOME
neuronal	I-OUTCOME
LSD	I-OUTCOME
-	I-OUTCOME
induced	I-OUTCOME
effects	I-OUTCOME
.	O
However	O
,	O
analyzing	O
the	O
time	O
course	O
of	O
LSD	B-DRUG
-	O
induced	O
alterations	B-NEURAL MECHANISM/CORRELATE
in	I-NEURAL MECHANISM/CORRELATE
functional	I-NEURAL MECHANISM/CORRELATE
connectivity	I-NEURAL MECHANISM/CORRELATE
,	O
it	O
seems	O
likely	O
that	O
at	O
a	O
later	O
phase	O
,	O
modulation	O
by	O
receptors	B-NEURAL MECHANISM/CORRELATE
other	O
than	O
the	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptor	O
is	O
involved	O
.	O
The	O
comparison	O
of	O
LSD	B-OUTCOME
-	I-OUTCOME
induced	I-OUTCOME
effects	I-OUTCOME
on	O
functional	B-NEURAL MECHANISM/CORRELATE
connectivity	I-NEURAL MECHANISM/CORRELATE
and	O
receptor	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
gene	I-NEURAL MECHANISM/CORRELATE
expression	I-NEURAL MECHANISM/CORRELATE
maps	I-NEURAL MECHANISM/CORRELATE
underscores	O
the	O
interpretations	O
of	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
pharmacology	O
and	O
points	O
to	O
potentially	O
impactful	O
studies	O
on	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT7	I-NEURAL MECHANISM/CORRELATE
receptor	O
pharmacology	O
.	O
Lastly	O
,	O
in	O
line	O
with	O
various	O
theories	O
of	O
consciousness	B-SUBJECTIVE EXPERIENCE
we	O
showed	O
that	O
the	O
somatomotor	B-NEURAL MECHANISM/CORRELATE
system	I-NEURAL MECHANISM/CORRELATE
in	O
particular	O
is	O
related	O
to	O
LSD	B-OUTCOME
-	I-OUTCOME
induced	I-OUTCOME
psychedelic	I-OUTCOME
effects	I-OUTCOME
.	O
Collectively	O
,	O
these	O
results	O
deepen	O
our	O
understanding	O
of	O
psychedelic	B-DRUG
compounds	I-DRUG
and	O
offer	O
important	O
directions	O
for	O
development	O
of	O
novel	O
therapeutics	O
.	O
-DOCSTART- -X- O O
The	O
Challenging	O
Experience	O
Questionnaire	O
(	O
CEQ	O
)	O
as	O
validated	O
in	O
this	O
report	O
may	O
serve	O
as	O
a	O
valuable	O
tool	O
for	O
characterizing	O
psychologically	B-OUTCOME
difficult	I-OUTCOME
aspects	I-OUTCOME
of	O
experiences	O
occasioned	O
by	O
psilocybin	B-DRUG
and	O
,	O
very	O
likely	O
,	O
by	O
other	O
classic	B-DRUG
hallucinogens	I-DRUG
.	O
Better	O
understanding	O
of	O
challenging	B-OUTCOME
experiences	I-OUTCOME
with	O
classic	B-DRUG
hallucinogens	I-DRUG
may	O
increase	O
the	O
precision	O
of	O
our	O
understanding	O
of	O
both	O
the	O
psychological	O
nature	O
of	O
and	O
neural	B-NEURAL MECHANISM/CORRELATE
mechanisms	I-NEURAL MECHANISM/CORRELATE
underlying	O
the	O
effects	O
of	O
these	O
drugs	O
.	O
Understanding	B-OUTCOME
challenging	I-OUTCOME
experiences	I-OUTCOME
with	O
classic	B-DRUG
hallucinogens	I-DRUG
may	O
also	O
facilitate	O
the	O
optimization	B-OUTCOME
of	I-OUTCOME
therapeutic	I-OUTCOME
application	I-OUTCOME
of	O
drugs	O
within	O
this	O
class	O
.	O
Thus	O
,	O
the	O
Challenging	O
Experience	O
Questionnaire	O
developed	O
in	O
this	O
report	O
makes	O
a	O
significant	O
contribution	O
to	O
methods	O
of	O
assessment	O
of	O
acute	O
psychologically	B-OUTCOME
adverse	I-OUTCOME
reactions	I-OUTCOME
to	O
psilocybin	B-DRUG
,	O
and	O
with	O
further	O
validation	O
,	O
will	O
likely	O
make	O
a	O
significant	O
contribution	O
to	O
methods	O
of	O
assessment	O
of	O
such	O
experiences	O
with	O
other	O
classic	B-DRUG
hallucinogens	I-DRUG
-DOCSTART- -X- O O
It	O
is	O
estimated	O
that	O
nearly	O
20	O
000	O
people	O
worldwide	O
are	O
members	O
of	O
some	O
of	O
the	O
Brazilian	O
ayahuasca	B-DRUG
religions	O
(	O
Santo	O
Daime	O
,	O
UDV	O
,	O
Barquinha	O
)	O
[	O
Labate	O
et	O
al	O
.	O
2009	O
]	O
.	O
The	O
scientific	O
literature	O
suggests	O
that	O
acute	O
ayahuasca	B-DRUG
administration	O
to	O
healthy	O
volunteers	O
has	O
a	O
good	B-OUTCOME
safety	I-OUTCOME
profile	I-OUTCOME
,	O
and	O
that	O
long	O
-	O
term	O
ritual	O
ayahuasca	B-DRUG
consumption	O
is	O
not	O
associated	O
with	O
cognitive	B-OUTCOME
or	I-OUTCOME
psychiatric	I-OUTCOME
problems	I-OUTCOME
[	O
dos	O
Santos	O
et	O
al	O
.	O
2016a	O
]	O
.	O
The	O
psychotic	B-OUTCOME
episodes	I-OUTCOME
described	O
in	O
the	O
present	O
systematic	O
review	O
are	O
apparently	O
associated	O
with	O
several	O
contributing	O
factors	O
,	O
and	O
not	O
only	O
ayahuasca	B-DRUG
or	O
DMT	B-DRUG
intake	O
.	O
Many	O
cases	O
involved	O
individuals	O
with	O
a	O
personal	O
or	O
family	O
history	O
of	O
psychosis	B-HEALTH CONDITION
or	O
nonpsychotic	B-HEALTH CONDITION
bipolar	I-HEALTH CONDITION
disorder	I-HEALTH CONDITION
,	O
or	O
concomitant	O
use	O
of	O
other	O
drugs	O
.	O
Therefore	O
,	O
these	O
individuals	O
have	O
a	O
different	O
profile	O
from	O
those	O
that	O
participate	O
in	O
controlled	O
studies	O
where	O
a	O
psychiatric	O
screening	O
is	O
performed	O
and	O
use	O
of	O
other	O
drugs	O
is	O
not	O
allowed	O
.	O
Moreover	O
,	O
in	O
controlled	O
studies	O
,	O
only	O
single	O
or	O
few	O
ayahuasca	B-DRUG
/	O
DMT	B-DRUG
doses	O
are	O
administered	O
,	O
and	O
in	O
some	O
cases	O
described	O
,	O
related	O
to	O
DMT	B-DRUG
use	O
,	O
the	O
subjects	O
have	O
used	O
several	O
doses	O
DMT	B-DRUG
before	O
the	O
subjects	O
psychotic	B-OUTCOME
episode	I-OUTCOME
Previous	O
reviews	O
of	O
adverse	B-OUTCOME
effects	I-OUTCOME
of	O
hallucinogens	B-DRUG
in	O
noncontrolled	O
/	O
recreational	O
settings	O
demonstrated	O
that	O
in	O
reports	O
‘	O
from	O
the	O
field	O
’	O
it	O
is	O
very	O
difficult	O
to	O
tease	O
apart	O
preexisting	O
psychopathology	O
,	O
drug	B-DRUG
/	O
alcohol	B-HEALTH CONDITION
abuse	I-HEALTH CONDITION
,	O
family	O
history	O
,	O
and	O
other	O
important	O
features	O
such	O
as	O
proper	O
preparation	O
,	O
guidance	O
,	O
and	O
integration	O
of	O
drug	B-OUTCOME
effects	I-OUTCOME
.	O
Thus	O
,	O
it	O
is	O
difficult	O
to	O
establish	O
a	O
causal	O
relationship	O
with	O
hallucinogen	B-DRUG
use	O
and	O
most	O
of	O
these	O
cases	O
[	O
Klock	O
et	O
al	O
.	O
1974	O
;	O
Strassman	O
,	O
1984	O
;	O
Johnson	O
et	O
al	O
.	O
2008	O
;	O
Smith	O
et	O
al	O
.	O
2014	O
;	O
Garcia	O
-	O
Romeu	O
et	O
al	O
.	O
2016	O
]	O
.	O
In	O
the	O
case	O
reports	O
described	O
in	O
the	O
present	O
review	O
,	O
it	O
is	O
similarly	O
difficult	O
to	O
determine	O
the	O
significance	O
of	O
ayahuasca	B-DRUG
/	O
DMT	B-DRUG
use	O
in	O
such	O
complicated	O
settings	O
,	O
especially	O
considering	O
the	O
safety	O
record	O
of	O
ayahuasca	B-DRUG
/	O
DMT	B-DRUG
administration	O
in	O
controlled	O
clinical	O
trials	O
where	O
rigorous	O
screening	O
,	O
supervision	O
,	O
and	O
follow	O
up	O
are	O
provided	O
Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
the	O
incidence	O
of	O
psychotic	B-OUTCOME
episodes	I-OUTCOME
associated	O
with	O
ayahuasca	B-DRUG
/	O
DMT	B-DRUG
intake	O
is	O
a	O
rare	O
phenomenon	O
,	O
and	O
these	O
rare	O
instances	O
appear	O
be	O
associated	O
with	O
previous	O
premorbid	O
characteristics	O
of	O
the	O
individuals	O
,	O
previous	O
and	O
possibly	O
concurrent	O
drug	B-HEALTH CONDITION
abuse	I-HEALTH CONDITION
,	O
and	O
lack	O
of	O
a	O
supervised	O
setting	O
.	O
Therefore	O
,	O
considering	O
the	O
possible	O
influence	O
of	O
these	O
and	O
other	O
factors	O
,	O
the	O
causal	O
relation	O
between	O
ayahuasca	B-DRUG
/	O
DMT	B-DRUG
and	O
these	O
cases	O
is	O
not	O
always	O
clear	O
.	O
These	O
data	O
suggest	O
that	O
performance	O
of	O
a	O
psychiatric	B-HEALTH CONDITION
and	I-HEALTH CONDITION
drug	I-HEALTH CONDITION
use	I-HEALTH CONDITION
history	I-HEALTH CONDITION
before	O
ayahuasca	B-DRUG
or	O
DMT	B-DRUG
administration	O
in	O
controlled	O
settings	O
may	O
reduce	O
the	O
occurrence	O
of	O
psychotic	B-OUTCOME
experiences	I-OUTCOME
.	O
Regarding	O
noncontrolled	O
/	O
recreational	O
use	O
,	O
individuals	O
with	O
personal	O
or	O
family	O
history	O
of	O
schizophrenia	B-HEALTH CONDITION
or	O
schizophreniform	B-HEALTH CONDITION
disorders	I-HEALTH CONDITION
,	O
psychotic	B-HEALTH CONDITION
depression	I-HEALTH CONDITION
or	O
mania	B-HEALTH CONDITION
,	O
or	O
with	O
ongoing	O
manic	B-HEALTH CONDITION
or	I-HEALTH CONDITION
psychotic	I-HEALTH CONDITION
symptomatology	I-HEALTH CONDITION
,	O
should	O
avoid	O
ayahuasca	B-DRUG
/	O
DMT	B-DRUG
intake	O
-DOCSTART- -X- O O
From	O
today	O
's	O
viewpoint	O
,	O
most	O
of	O
the	O
studies	O
before	O
the	O
year	O
2000	O
show	O
strong	O
methodological	O
limitations	O
.	O
While	O
early	O
results	O
were	O
mainly	O
based	O
on	O
anecdotal	O
evidence	O
,	O
later	O
results	O
were	O
based	O
on	O
non	O
-	O
standardized	O
outcome	O
criteria	O
and	O
were	O
not	O
compared	O
with	O
any	O
control	O
group	O
.	O
Additionally	O
,	O
no	O
long	O
-	O
term	O
follow	O
-	O
up	O
studies	O
of	O
the	O
patients	O
were	O
carried	O
out	O
.	O
In	O
regard	O
to	O
the	O
open	O
study	O
design	O
the	O
trials	O
carry	O
a	O
high	O
risk	O
of	O
bias	O
.	O
Most	O
studies	O
also	O
lack	O
detailed	O
methodical	O
descriptions	O
of	O
the	O
populations	O
,	O
diagnosis	O
methods	O
,	O
psychotherapeutic	O
interventions	O
and	O
statistical	O
analysis	O
Nevertheless	O
,	O
recent	O
double	O
-	O
blind	O
,	O
randomized	O
and	O
controlled	O
studies	O
show	O
some	O
limitations	O
in	O
recent	O
double	O
-	O
blind	O
,	O
randomized	O
and	O
controlled	O
studies	O
study	O
set	O
-	O
up	O
.	O
The	O
blinding	O
process	O
is	O
only	O
possible	O
to	O
a	O
limited	O
extent	O
since	O
psychedelics	B-DRUG
produce	O
unique	B-OUTCOME
characteristic	I-OUTCOME
psychoactive	I-OUTCOME
effects	I-OUTCOME
,	O
which	O
reveal	O
the	O
allocation	O
in	O
treatment	O
or	O
control	O
group	O
to	O
patient	O
and	O
therapist	O
(	O
Gasser	O
et	O
al	O
.	O
,	O
2014a	O
;	O
Grob	O
et	O
al	O
.	O
,	O
2011	O
;	O
Mogar	O
,	O
1967	O
;	O
Salzman	O
and	O
Hicks	O
,	O
1969	O
)	O
.	O
Methods	O
to	O
counteract	O
this	O
phenomenon	O
are	O
the	O
administration	O
of	O
the	O
active	O
placebo	O
niacin	O
or	O
small	O
dosages	O
of	O
the	O
psychedelic	B-DRUG
compound	I-DRUG
but	O
are	O
only	O
successful	O
to	O
a	O
limited	O
extent	O
.	O
Therefore	O
,	O
in	O
combination	O
with	O
the	O
subjective	B-OUTCOME
outcome	I-OUTCOME
measures	I-OUTCOME
based	O
on	O
clinician-	O
and	O
patient	O
-	O
administered	O
rating	O
scales	O
,	O
recent	O
studies	O
still	O
carry	O
a	O
risk	O
of	O
bias	O
.	O
Furthermore	O
,	O
the	O
obtained	O
follow	O
-	O
up	O
data	O
are	O
only	O
conclusive	O
to	O
a	O
limited	O
extent	O
,	O
after	O
control	O
groups	O
have	O
also	O
received	O
an	O
active	O
therapeutic	O
dose	O
of	O
the	O
psychedelic	B-DRUG
compound	I-DRUG
within	O
the	O
applied	O
cross	O
-	O
over	O
design	O
.	O
The	O
authors	O
argued	O
that	O
the	O
reason	O
for	O
the	O
uncontrolled	O
study	O
design	O
in	O
the	O
early	O
studies	O
and	O
the	O
cross	O
-	O
over	O
design	O
in	O
more	O
recent	O
studies	O
,	O
were	O
also	O
because	O
of	O
ethical	O
reasons	O
,	O
since	O
it	O
would	O
be	O
ethically	O
questionable	O
to	O
withhold	O
a	O
potential	B-OUTCOME
beneficial	I-OUTCOME
treatment	I-OUTCOME
concept	O
or	O
to	O
run	O
a	O
placebo	O
control	O
group	O
over	O
such	O
a	O
long	O
period	O
in	O
regard	O
to	O
the	O
patient	O
's	O
severe	B-HEALTH CONDITION
illness	I-HEALTH CONDITION
and	O
reduced	O
life	O
expectancy	O
(	O
Gasser	O
et	O
al	O
.	O
,	O
2014b	O
;	O
Grob	O
et	O
al	O
.	O
,	O
2013	O
,	O
Grob	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O
With	O
regard	O
to	O
the	O
generalizability	O
of	O
the	O
results	O
,	O
the	O
strict	O
exclusion	O
criteria	O
(	O
see	O
below	O
)	O
under	O
which	O
the	O
patients	O
for	O
the	O
studies	O
have	O
been	O
recruited	O
constitute	O
a	O
restriction	O
.	O
Also	O
,	O
the	O
high	O
percentage	O
of	O
highly	O
educated	O
people	O
in	O
the	O
population	O
and	O
the	O
fact	O
that	O
around	O
half	O
of	O
the	O
patients	O
reported	O
a	O
prior	O
history	O
of	O
hallucinogen	B-DRUG
use	O
in	O
recent	O
studies	O
(	O
Griffiths	O
et	O
al	O
.	O
,	O
2016	O
;	O
Ross	O
et	O
al	O
.	O
,	O
2016	O
)	O
,	O
further	O
limits	O
the	O
generalizability	O
.	O
In	O
conclusion	O
,	O
there	O
is	O
some	O
evidence	O
that	O
substance	O
-	O
assisted	O
psychotherapy	O
with	O
serotonergic	B-DRUG
hallucinogens	I-DRUG
is	O
effective	O
in	O
the	O
treatment	O
of	O
mental	B-HEALTH CONDITION
health	I-HEALTH CONDITION
problems	I-HEALTH CONDITION
in	O
patients	O
with	O
a	O
life	B-HEALTH CONDITION
-	I-HEALTH CONDITION
threatening	I-HEALTH CONDITION
disease	I-HEALTH CONDITION
and	O
is	O
well	O
tolerated	O
.	O
Moreover	O
,	O
there	O
is	O
some	O
evidence	O
that	O
psychedelic	O
-	O
induced	O
mystical	B-SUBJECTIVE EXPERIENCE
-	I-SUBJECTIVE EXPERIENCE
type	I-SUBJECTIVE EXPERIENCE
peak	I-SUBJECTIVE EXPERIENCE
experiences	I-SUBJECTIVE EXPERIENCE
mediate	O
not	O
only	O
reduction	B-OUTCOME
of	I-OUTCOME
psychiatric	I-OUTCOME
symptoms	I-OUTCOME
in	O
these	O
patients	O
,	O
but	O
may	O
also	O
be	O
helpful	O
for	O
these	O
patients	O
by	O
improving	B-OUTCOME
disease	I-OUTCOME
coping	I-OUTCOME
and	O
quality	B-OUTCOME
of	I-OUTCOME
life	I-OUTCOME
when	O
facing	O
a	O
life	O
-	O
threatening	O
condition	O
.	O
Given	O
the	O
reasonable	B-OUTCOME
safety	I-OUTCOME
profile	I-OUTCOME
of	O
serotonergic	B-DRUG
hallucinogens	I-DRUG
in	O
a	O
controlled	O
clinical	O
environment	O
,	O
psychedelic	B-DRUG
-	O
assisted	O
psychotherapy	O
could	O
be	O
a	O
promising	O
treatment	O
option	O
in	O
this	O
context	O
–	O
especially	O
for	O
patients	O
where	O
other	O
approaches	O
have	O
been	O
ineffective	O
.	O
Hence	O
,	O
additional	O
trials	O
are	O
needed	O
to	O
evaluate	O
whether	O
the	O
presented	O
results	O
can	O
be	O
transferred	O
in	O
to	O
clinical	O
practice	O
.	O
-DOCSTART- -X- O O
The	O
resurrection	O
of	O
research	O
into	O
the	O
neuroscience	O
and	O
therapeutic	B-OUTCOME
application	I-OUTCOME
of	O
psychedelics	B-DRUG
represents	O
one	O
of	O
the	O
most	O
important	O
initiatives	O
in	O
psychiatry	O
and	O
brain	B-NEURAL MECHANISM/CORRELATE
science	O
in	O
recent	O
decades	O
.	O
The	O
resurrection	O
of	O
research	O
into	O
the	O
neuroscience	O
and	O
therapeutic	B-OUTCOME
application	I-OUTCOME
of	O
psychedelics	B-DRUG
rectifies	O
decades	O
of	O
global	O
research	O
paralysis	O
that	O
emerged	O
as	O
collateral	O
damage	O
from	O
the	O
war	O
on	O
drugs	O
and	O
that	O
has	O
become	O
one	O
of	O
the	O
worst	O
examples	O
of	O
censorship	O
of	O
human	O
research	O
in	O
the	O
history	O
of	O
science	O
.	O
The	O
past	O
ten	O
years	O
have	O
seen	O
the	O
first	O
green	O
shoots	O
of	O
recovery	O
with	O
a	O
number	O
of	O
teams	O
across	O
several	O
continents	O
beginning	O
human	O
neuroimaging	O
and	O
clinical	O
trials	O
that	O
have	O
delivered	O
remarkable	O
insights	O
into	O
brain	B-NEURAL MECHANISM/CORRELATE
function	I-NEURAL MECHANISM/CORRELATE
and	O
instigated	O
an	O
exciting	O
new	O
approach	O
to	O
the	O
treatment	O
of	O
a	O
range	O
of	O
psychiatric	B-HEALTH CONDITION
disorders	I-HEALTH CONDITION
(	O
Table	O
1	O
)	O
.	O
What	O
is	O
now	O
needed	O
is	O
a	O
combined	O
,	O
multi	O
-	O
level	O
,	O
multidisciplinary	O
program	O
of	O
research	O
into	O
the	O
mechanisms	O
underpinning	O
these	O
findings	O
.	O
-DOCSTART- -X- O O
Neuropsychological	O
studies	O
have	O
demonstrated	O
impaired	O
performance	B-OUTCOME
of	I-OUTCOME
working	I-OUTCOME
memory	I-OUTCOME
in	O
AYA	B-DRUG
users	O
under	O
the	O
influence	O
of	O
the	O
substance	O
and	O
better	O
performance	B-OUTCOME
in	I-OUTCOME
other	I-OUTCOME
executive	I-OUTCOME
functions	I-OUTCOME
such	O
as	O
planning	B-OUTCOME
and	O
inhibitory	B-OUTCOME
control	I-OUTCOME
(	O
after	O
acute	O
and	O
long	O
-	O
term	O
AYA	B-DRUG
intake	O
)	O
in	O
experienced	O
users	O
compared	O
to	O
occasional	O
users	O
and	O
non	O
-	O
users	O
.	O
Research	O
with	O
neuroimaging	O
showed	O
the	O
activation	O
of	O
frontal	B-NEURAL MECHANISM/CORRELATE
and	I-NEURAL MECHANISM/CORRELATE
paralimbic	I-NEURAL MECHANISM/CORRELATE
brain	I-NEURAL MECHANISM/CORRELATE
regions	I-NEURAL MECHANISM/CORRELATE
.	O
The	O
controlled	O
/	O
ritualistic	O
use	O
of	O
AYA	B-DRUG
has	O
a	O
good	B-OUTCOME
safety	I-OUTCOME
profile	I-OUTCOME
,	O
and	O
recent	O
research	O
has	O
suggested	O
that	O
AYA	B-DRUG
can	O
have	O
therapeutic	B-OUTCOME
effects	I-OUTCOME
on	I-OUTCOME
the	I-OUTCOME
remission	I-OUTCOME
of	O
some	O
psychiatric	B-HEALTH CONDITION
disorders	I-HEALTH CONDITION
such	O
as	O
major	B-HEALTH CONDITION
depression	I-HEALTH CONDITION
and	O
substance	B-HEALTH CONDITION
dependence	I-HEALTH CONDITION
However	O
,	O
these	O
preliminary	O
studies	O
were	O
not	O
controlled	O
and	O
the	O
long	O
-	O
term	O
effects	O
of	O
AYA	B-DRUG
,	O
as	O
well	O
as	O
the	O
mechanisms	O
of	O
action	O
responsible	O
for	O
these	O
effects	O
,	O
are	O
still	O
largely	O
unknown	O
and	O
therefore	O
need	O
to	O
be	O
further	O
clarified	O
.	O
Thus	O
,	O
the	O
lack	O
of	O
studies	O
highlights	O
important	O
gaps	O
,	O
such	O
as	O
the	O
aforementioned	O
lack	O
of	O
research	O
with	O
children	O
and	O
pregnant	O
women	O
who	O
drink	O
the	O
tea	O
.	O
Another	O
factor	O
which	O
indicates	O
the	O
need	O
for	O
more	O
research	O
is	O
the	O
lack	O
of	O
studies	O
with	O
populations	O
that	O
have	O
health	B-HEALTH CONDITION
problems	I-HEALTH CONDITION
,	O
considering	O
that	O
the	O
tests	O
carried	O
out	O
had	O
exclusion	O
criteria	O
for	O
psychiatric	B-HEALTH CONDITION
and	O
other	B-HEALTH CONDITION
diseases	I-HEALTH CONDITION
.	O
Furthermore	O
,	O
more	O
studies	O
assessing	O
the	O
effects	O
of	O
AYA	B-DRUG
in	O
naïve	O
users	O
are	O
needed	O
considering	O
that	O
most	O
studies	O
conducted	O
so	O
far	O
assessed	O
experienced	O
AYA	B-DRUG
consumers	O
,	O
which	O
may	O
limit	O
the	O
generalizability	O
of	O
the	O
results	O
since	O
these	O
individuals	O
are	O
well	O
adapted	O
to	O
long	O
-	O
term	O
AYA	B-DRUG
use	O
Therefore	O
,	O
more	O
research	O
is	O
necessary	O
to	O
better	O
understand	O
the	O
effects	O
of	O
AYA	B-DRUG
and	O
AYA	B-DRUG
therapeutic	B-OUTCOME
potentials	I-OUTCOME
,	O
avoiding	O
the	O
reckless	O
spread	O
of	O
information	O
devoid	O
of	O
scientific	O
basis	O
,	O
which	O
may	O
interfere	O
with	O
the	O
conduct	O
adopted	O
in	O
clinical	O
practice	O
(	O
Dos	O
Santos	O
et	O
al	O
.	O
,	O
2013b	O
,	O
2016	O
)	O
.	O
-DOCSTART- -X- O O
This	O
effective	O
connectivity	B-NEURAL MECHANISM/CORRELATE
study	O
shows	O
that	O
a	O
decrease	B-OUTCOME
of	I-OUTCOME
top	I-OUTCOME
-	I-OUTCOME
down	I-OUTCOME
connectivity	I-OUTCOME
from	O
the	B-NEURAL MECHANISM/CORRELATE
AMG	I-NEURAL MECHANISM/CORRELATE
to	O
the	O
visual	B-NEURAL MECHANISM/CORRELATE
cortex	I-NEURAL MECHANISM/CORRELATE
underlies	O
the	O
psilocybin	B-DRUG
effect	O
on	O
visual	B-OUTCOME
threat	I-OUTCOME
processing	I-OUTCOME
.	O
This	O
result	O
suggests	O
that	O
decreased	B-OUTCOME
threat	I-OUTCOME
sensitivity	I-OUTCOME
in	O
the	O
visual	B-NEURAL MECHANISM/CORRELATE
cortex	I-NEURAL MECHANISM/CORRELATE
during	O
emotion	B-OUTCOME
processing	I-OUTCOME
may	O
explain	O
the	O
potential	O
of	O
psilocybin	B-DRUG
to	O
acutely	O
shift	B-OUTCOME
emotional	I-OUTCOME
biases	I-OUTCOME
away	I-OUTCOME
from	I-OUTCOME
negative	I-OUTCOME
towards	I-OUTCOME
positive	I-OUTCOME
valence	O
:	O
the	O
capacity	O
of	O
the	O
visual	B-NEURAL MECHANISM/CORRELATE
cortex	I-NEURAL MECHANISM/CORRELATE
to	O
process	O
multiple	O
stimuli	O
is	O
limited	O
and	O
hence	O
top	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
down	I-NEURAL MECHANISM/CORRELATE
suppression	I-NEURAL MECHANISM/CORRELATE
of	I-NEURAL MECHANISM/CORRELATE
negative	I-NEURAL MECHANISM/CORRELATE
stimuli	I-NEURAL MECHANISM/CORRELATE
enhances	O
the	O
processing	B-OUTCOME
of	I-OUTCOME
positive	I-OUTCOME
stimuli	I-OUTCOME
(	O
Kastner	O
et	O
al	O
.	O
,	O
1998	O
)	O
.	O
This	O
may	O
have	O
important	O
therapeutic	O
implications	O
for	O
mood	B-SUBJECTIVE EXPERIENCE
and	O
anxiety	B-HEALTH CONDITION
disorders	O
,	O
where	O
over	O
-	O
loading	O
with	O
negative	O
stimuli	O
and	O
persistence	O
of	O
negative	O
cognitive	O
biases	O
is	O
a	O
central	O
feature	O
(	O
Disner	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O
In	O
post	B-HEALTH CONDITION
-	I-HEALTH CONDITION
traumatic	I-HEALTH CONDITION
stress	I-HEALTH CONDITION
disorder	I-HEALTH CONDITION
,	O
for	O
example	O
,	O
psilocybin	B-DRUG
might	O
help	O
inhibit	B-OUTCOME
fear	I-OUTCOME
-	I-OUTCOME
responses	I-OUTCOME
during	O
exposure	O
-	O
based	O
psychotherapy	O
,	O
which	O
might	O
facilitate	O
therapeutic	O
progress	O
.	O
-DOCSTART- -X- O O
Results	O
of	O
this	O
randomized	O
clinical	O
trial	O
demonstrated	O
the	O
efficacy	O
of	O
psilocybin	B-DRUG
-	O
assisted	O
therapy	O
in	O
producing	O
large	B-OUTCOME
,	I-OUTCOME
rapid	I-OUTCOME
,	I-OUTCOME
and	I-OUTCOME
sustained	I-OUTCOME
antidepressant	I-OUTCOME
effects	I-OUTCOME
among	O
patients	O
with	O
MDD	B-HEALTH CONDITION
.	O
These	O
data	O
expand	O
the	O
findings	O
of	O
previous	O
studies	O
involving	O
patients	O
with	O
cancer	B-HEALTH CONDITION
and	O
depression	B-HEALTH CONDITION
as	O
well	O
as	O
patients	O
with	O
treatment	B-HEALTH CONDITION
-	I-HEALTH CONDITION
resistant	I-HEALTH CONDITION
depression	I-HEALTH CONDITION
by	O
suggesting	O
that	O
psilocybin	B-DRUG
may	O
be	O
effective	O
in	O
the	O
much	O
larger	O
population	O
of	O
MDD	B-HEALTH CONDITION
.	O
Further	O
studies	O
are	O
needed	O
with	O
active	O
treatment	O
or	O
placebo	O
controls	O
and	O
in	O
larger	O
and	O
more	O
diverse	O
populations	O
.	O